<!DOCTYPE html>
<html lang="en">
<head>
    <meta charset="utf-8">
    <meta http-equiv="X-UA-Compatible" content="IE=edge">
    <meta content="width=device-width, initial-scale=1, maximum-scale=1, user-scalable=no" name="viewport">
    <meta name="description" content="نظام معلومات الأدوية السعودي Saudi Drugs Information System">
    <meta name="author" content="Saudi Food & Drug Authority (SFDA)">
    <noscript><meta http-equiv="refresh" content="0; url=/noScript.html" /></noscript>
    <link rel="shortcut icon" href="/favicon.ico">
    <title>&#x646;&#x638;&#x627;&#x645; &#x645;&#x639;&#x644;&#x648;&#x645;&#x627;&#x62A; &#x627;&#x644;&#x623;&#x62F;&#x648;&#x64A;&#x629;</title>
    <link href="/fonts/roboto/roboto.css?v=53F8z0aw8DRnG9ou9x1tuKMPbNjRZWM-VBHl3B0s9-o" rel="stylesheet" />
    <link href="/fonts/material-icons/materialicons.css?v=8pEJ8MWsFzHRDLY0NI5rssf6T6vankxrJDPnnZxOGrg" rel="stylesheet" />
    <link href="/lib/bootstrap/dist/css/bootstrap-rtl.css?v=0env-Atj9mTPLILmJGwuDlLIOS_Akxxy4gnH1UUtrjU" rel="stylesheet" />
    <link href="/lib/bootstrap/dist/css/bootstrap-glyphicons.css?v=U5a39oen_WYzVAAexH5aoahbpqlKHcIzQrnXujf1yio" rel="stylesheet" />
    <link href="/lib/bootstrap-select/dist/css/bootstrap-select.css?v=DeY2lH0e0tmNnO9XZ-gGVOGk6_YoWlZ49y7CnD3ST00" rel="stylesheet" />
    <link href="/lib/toastr/toastr.css?v=kKePN_CyxTiMEgsSDu_7z21ru07YOZtR-0UV0JOkt5o" rel="stylesheet" />
    <link href="/lib/famfamfam-flags/dist/sprite/famfamfam-flags.css?v=JVJiF3s2_kk99xQHfYhfxo_-Dd52ZIruDMOILwPkqv0" rel="stylesheet" />
    <link href="/lib/font-awesome/css/font-awesome.css?v=YIHlqxkiJtENTMuzIHC9EfZaB5RniGr7kF7juUQJUuc" rel="stylesheet" />
    <link href="/lib/Waves/dist/waves.css?v=nd3hxjNg6DhkuFIz5IbxLK8Xw2ac0blsDQpF4pkJxUc" rel="stylesheet" />
    <link href="/lib/animate.css/animate.css?v=IT6GQizZpVcaM1_L_mIiNAYVvZErMgfwewf1GGWXG_I" rel="stylesheet" />
    <link href="/css/materialize.css?v=ey-J3xahkqficOYUHVX3jexmzvRFrge9bmux4CQr1DQ" rel="stylesheet" />
    <link href="/css/Publicstyle.css?v=xhOiVjq-54ODzSIeHXoascHsEJm_n_bIHqZatpxnYhg" rel="stylesheet">
    <link href="/css/Comman.css?v=bcS6_IRqBsBcY1mS_iriWWanrYR0Scdo1ffk8rQGXwQ" rel="stylesheet" />
    <link href="/css/themes/all-themes.css?v=eGSl5zNTWrXYfUx_EJW9ksC3CUTUUxvxmPiA3aQDtQo" rel="stylesheet" />
    <link href="/view-resources/Views/Shared/_Layout.css?v=BLxBuNISlF2O5EBHWdsX039NvnIHy-GtcqeI_MbyIc0" rel="stylesheet" />
    <link href="/lib/enjoyhint/enjoyhint.css?v=rSxIyBbiAvx_48ZcFxbn2DNPCCgEc0FXa2Vb72enxk4" rel="stylesheet" />
    <link href="/lib/dropzone/dropzone.css?v=IQDlHJdeYZ4gMH87EuB1yEG7ujA7DSEkV_SWfACk8Rg" rel="stylesheet" />

    <!-- View specific styles -->
    
    <script type="text/javascript" nonce="c7f26c8w">
        // This is used to get the application's root path from javascript. It's useful if you're running application in a virtual directory under IIS.
        var abp = abp || {};
        abp.appPath = '/';

    </script>
    <style>
        .popover .popover-title {
            text-align: right;
            font-weight: bold;
        }
        .popover .popover-content {
            text-align: right;
            font-size: 14px;
            font-family: 'Almarai', sans-serif;
            color: black;
        }
       
    </style>
</head>
<body>
    <!-- Page Loader -->
    <div class="page-loader-wrapper">
        <div class="loader">
            <div class="preloader">
                <div class="spinner-layer pl-blue">
                    <div class="circle-clipper left">
                        <div class="circle"></div>
                    </div>
                    <div class="circle-clipper right">
                        <div class="circle"></div>
                    </div>
                </div>
            </div>
            <p>&#x628;&#x631;&#x62C;&#x627;&#x621; &#x627;&#x644;&#x625;&#x646;&#x62A;&#x638;&#x627;&#x631; ...</p>
        </div>
    </div>
    <!-- #END# Page Loader -->
    <!-- Overlay For Sidebars -->
    <div class="overlay"></div>
    <!-- #END# Overlay For Sidebars -->
    <!-- Search Bar -->
    <!-- Top Bar -->
    <nav class="navbar navbar-inverse naav" style="margin-bottom: 0;">
        <div class="container-fluid">
            <div class="navbar-header">
                <button type="button" class="navbar-toggle" data-toggle="collapse" data-target="#myNavbar">
                    <span class="icon-bar"></span>
                    <span class="icon-bar"></span>
                    <span class="icon-bar"></span>
                </button>
            </div>
            <div class="collapse navbar-collapse rtl" id="navbar-collapse">
                <ul class="nav navbar-nav navbar-right">
                    <li><a href="/home/DrugSearch">&#x627;&#x644;&#x623;&#x62F;&#x648;&#x64A;&#x629;</a></li>
                        <li><a href="/Account/Login"><i class="fa fa-key"></i>&nbsp;&#x62A;&#x633;&#x62C;&#x64A;&#x644; &#x627;&#x644;&#x62F;&#x62E;&#x648;&#x644;</a></li>
                </ul>
                <ul class="nav navbar-nav navbar-left">
                    <li class="dropdown">
    <a href="javascript:void(0);" class="dropdown-toggle" data-toggle="dropdown" role="button">
        <i class="famfamfam-flags sa" title="&#x627;&#x644;&#x639;&#x631;&#x628;&#x64A;&#x629;"></i>
        <span>&#x627;&#x644;&#x639;&#x631;&#x628;&#x64A;&#x629;</span>
        <b class="caret"></b>
    </a>
    <ul class="dropdown-menu pull-right">
                <li><a href="/AbpLocalization/ChangeCulture?cultureName=en"><i class="famfamfam-flags gb"></i> English</a></li>

    </ul>
</li>

                </ul>
            </div>
        </div>
    </nav>
    <section id="mainContent" class="content">
        <nav class="navbar naav" style="margin-bottom: 0;">
            <div class="container-fluid">
                <ul class="nav navbar-nav">
                    <li>
                        <a class="text-center" href="/">
                            <img src="/images/logo_sdi.png" style="margin: auto;" width="250">
                        </a>
                    </li>
                </ul>
                <div class="navbar-header navbar-toggle2 ">
                    <button type="button" class="navbar-toggle navbar-toggle2" data-toggle="collapse"
                            data-target="#myNavbar2">
                        <span class="icon-bar icon-bar2 "></span>
                        <span class="icon-bar icon-bar2"></span>
                        <span class="icon-bar icon-bar2"></span>
                    </button>
                </div>
                <div class="collapse navbar-collapse " id="myNavbar2">
                    <ul class="nav navbar-nav">
                        <li>
                            <a href="#" class="text-right waves-effect" data-trigger="focus"
                               style="color: #4276a1;" data-container="body" data-toggle="popover" data-placement="bottom" title="" data-content="موقع الكترونى يمكن شركات ووكلاء الادويه من رفع النشرات الممارس الصحى ونشرة معلومات المريض وصورة عبوة الدواء المعتمدة من الهيئة العامة للعذاء والدواء بهدف بناء مرجع وطنى للادوية المسجلة يمكن الرجوع له من قبل الممارس الصحى والمريض كمصدر موثوق للمعلومات الدوائية"
                               data-original-title="&#x645;&#x646; &#x646;&#x62D;&#x646;">
                                &#x645;&#x646; &#x646;&#x62D;&#x646;
                            </a>
                        </li>
                        <li>
                            <a href="#" class="text-right waves-effect" data-trigger="focus"
                               style="color: #4276a1;" data-container="body" data-toggle="popover"
                               data-placement="bottom"
                               title=""
                               data-content="&#x627;&#x630;&#x627; &#x643;&#x627;&#x646; &#x644;&#x62F;&#x64A;&#x643;&#x645; &#x645;&#x644;&#x627;&#x62D;&#x638;&#x627;&#x62A; &#x627;&#x648; &#x627;&#x642;&#x62A;&#x631;&#x627;&#x62D;&#x627;&#x62A; &#x64A;&#x631;&#x62C;&#x649; &#x627;&#x644;&#x62A;&#x648;&#x627;&#x635;&#x644; &#x639;&#x644;&#x649;   SDI@SFDA.GOV.SA"
                               data-original-title="&#x62A;&#x648;&#x627;&#x635;&#x644; &#x645;&#x639;&#x646;&#x627;">
                                &#x62A;&#x648;&#x627;&#x635;&#x644; &#x645;&#x639;&#x646;&#x627;
                            </a>
                        </li>

                    </ul>
                </div>
            </div>
        </nav>
        

<div class="col-xs-12">
    <div class="row text-center">
        <a href="/" class="btn bg-blue btn-lg m-b-10 hover-white">&#x628;&#x62D;&#x62B; &#x62C;&#x62F;&#x64A;&#x62F;</a>
    </div>
</div>
<div class="jumbotron" style="margin-bottom: 0px; background-color: white !important;">
    <h3 class="text-center" style="color: #57aabf; ">Search Results</h3>
    <hr width="20%" style="border-top: 3px solid #54ae90;">

    <br>
    <table class="table s-row">
        <thead style="margin-bottom: 30px !important">
                <tr>
                    <th id="M" style="color:white;">
                        <a href="javascript:void(0)"
                           style="color: white;">&#x646;&#x634;&#x631;&#x629; &#x627;&#x644;&#x645;&#x645;&#x627;&#x631;&#x633; &#x627;&#x644;&#x635;&#x62D;&#x64A;</a>
                    </th>
                    <th id="A" style="color:white;" type='button'>
                        <a href="javascript:void(0)"
                           style="color: white;">&#x646;&#x634;&#x631;&#x629; &#x645;&#x639;&#x644;&#x648;&#x645;&#x627;&#x62A; &#x627;&#x644;&#x645;&#x631;&#x64A;&#x636; &#x628;&#x627;&#x644;&#x639;&#x631;&#x628;&#x64A;&#x629;</a>
                    </th>
                    <th id="E" style="color:white;" type='button'>
                        <a href="javascript:void(0)"
                           style="color: white;">&#x646;&#x634;&#x631;&#x629; &#x645;&#x639;&#x644;&#x648;&#x645;&#x627;&#x62A; &#x627;&#x644;&#x645;&#x631;&#x64A;&#x636; &#x628;&#x627;&#x644;&#x627;&#x646;&#x62C;&#x644;&#x64A;&#x632;&#x64A;&#x629;</a>
                    </th>
                    <th id="f" class="active-tab" type='button'>
                        <a href="javascript:void(0)" style="color: white;">&#x635;&#x648;&#x631; &#x627;&#x644;&#x62F;&#x648;&#x627;&#x621;</a>
                    </th>
                    <th id="D" style="color:white; background-color: #47a4ba;" type='button'>
                        <a href="javascript:void(0)"
                           style="color: white;">&#x628;&#x64A;&#x627;&#x646;&#x627;&#x62A; &#x627;&#x644;&#x62F;&#x648;&#x627;&#x621;</a>
                    </th>

                </tr>
        </thead>
    </table>
    <div id="D-div" class="box-data" style="display: block;">
        <div class="row">

<div class="modal-body rtl">
    <div class="tab-content">
        <div role="tabpanel" class="tab-pane m-r-60  animated fadeIn active" id="edit-user-details">
<div class="row clearfix">
                    <div class="col-lg-6 col-md-6 col-sm-6">
                        <div class="row clearfix">
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label" for="RegisterNumber">&#x631;&#x642;&#x645; &#x627;&#x644;&#x62A;&#x633;&#x62C;&#x64A;&#x644;</label>
                                    <div class="form-line">
                                        0305233585
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label col-view" for="RegisterYear">&#x633;&#x646;&#x629; &#x627;&#x644;&#x62A;&#x633;&#x62C;&#x64A;&#x644;</label>
                                    <div class="form-line">
                                        2016
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label col-view" for="TradeName">&#x627;&#x644;&#x627;&#x633;&#x645; &#x627;&#x644;&#x62A;&#x62C;&#x627;&#x631;&#x64A;</label>
                                    <div class="form-line">
                                        BRINTELLIX 10 mg film-coated tablet
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label col-view" for="ScientificName">&#x627;&#x644;&#x627;&#x633;&#x645; &#x627;&#x644;&#x639;&#x644;&#x645;&#x64A;</label>
                                    <div class="form-line">
                                        VORTIOXETINE
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label " for="Strength">&#x627;&#x644;&#x62A;&#x631;&#x643;&#x64A;&#x632;</label>
                                    <div class="form-line">
                                        10
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label" for="StrengthUnitName">&#x648;&#x62D;&#x62F;&#x629; &#x627;&#x644;&#x62A;&#x631;&#x643;&#x64A;&#x632;</label>
                                    <div class="form-line">
                                        mg
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label" for="AdministrationRouteName">&#x637;&#x631;&#x64A;&#x642;&#x629; &#x627;&#x644;&#x625;&#x633;&#x62A;&#x639;&#x645;&#x627;&#x644;</label>
                                    <div class="form-line">
                                        Oral use
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="PharmaceuticalFormName">&#x627;&#x644;&#x634;&#x643;&#x644; &#x627;&#x644;&#x635;&#x64A;&#x62F;&#x644;&#x627;&#x646;&#x64A;</label>
                                    <div class="form-line">
                                        Film-coated tablet
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="Size">&#x627;&#x644;&#x62D;&#x62C;&#x645;</label>
                                    <div class="form-line">
                                        
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="SizeUnitName">&#x648;&#x62D;&#x62F;&#x629; &#x627;&#x644;&#x62D;&#x62C;&#x645;</label>
                                    <div class="form-line">
                                        
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="PackageSize">&#x62D;&#x62C;&#x645; &#x627;&#x644;&#x639;&#x628;&#x648;&#x629;</label>
                                    <div class="form-line">
                                        28
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="PackageTypeName">&#x627;&#x646;&#x648;&#x627;&#x639; &#x627;&#x644;&#x639;&#x628;&#x648;&#x627;&#x62A;</label>
                                    <div class="form-line">
                                        Blister
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="LegalStatusName">&#x637;&#x631;&#x64A;&#x642;&#x629; &#x627;&#x644;&#x635;&#x631;&#x641;</label>
                                    <div class="form-line">
                                        Prescription
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label" for="ProductControlName">&#x62D;&#x627;&#x644;&#x629; &#x627;&#x644;&#x645;&#x631;&#x627;&#x642;&#x628;&#x629;</label>
                                    <div class="form-line">
                                        Uncontrolled
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="DrugTypeName">&#x646;&#x648;&#x639; &#x627;&#x644;&#x62F;&#x648;&#x627;&#x621;</label>
                                    <div class="form-line">
                                        NCE
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="ShelfLife">&#x645;&#x62F;&#x629; &#x627;&#x644;&#x635;&#x644;&#x627;&#x62D;&#x64A;&#x629; &#x628;&#x627;&#x644;&#x623;&#x634;&#x647;&#x631;</label>
                                    <div class="form-line">
                                        48
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="StorageConditionsName">&#x634;&#x631;&#x648;&#x637; &#x627;&#x644;&#x62A;&#x62E;&#x632;&#x64A;&#x646;</label>
                                    <div class="form-line">
                                        store below 30°c
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="Price">&#x633;&#x639;&#x631; &#x627;&#x644;&#x62C;&#x645;&#x647;&#x648;&#x631; &#x628;&#x627;&#x644;&#x631;&#x64A;&#x627;&#x644;  ( &#x627;&#x644;&#x633;&#x639;&#x631; )</label>
                                    <div class="form-line">
                                        140.65
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                                <div class="col-sm-6 col-lg-6">
                                    <div class="form-group">
                                        <input type="hidden" id="Manufacture_NameEn" name="Manufacture.NameEn" value="H. LUNDBECK" />
                                        <label class="form-label" for="Manufacture_NameEn">&#x627;&#x644;&#x645;&#x635;&#x646;&#x639;</label>
                                        <div class="form-line">
                                            H. LUNDBECK
                                        </div>
                                    </div>
                                </div>
                                <div class="col-sm-6 col-lg-6">
                                    <div class="form-group">
                                        <input type="hidden" id="Agent" name="Agent" value="[Agent 354]" />
                                        <label class="form-label">&#x627;&#x644;&#x648;&#x643;&#x64A;&#x644;</label>
                                        <div class="form-line">
                                            SAUDI INTERNATIONAL TRADING COMPANY LTD (SITCO)
                                        </div>
                                    </div>
                                </div>
                                <div class="col-sm-6 col-lg-6">
                                    <div class="form-group">
                                        <label class="form-label" for="Company_NameEn">&#x627;&#x644;&#x634;&#x631;&#x643;&#x629; &#x627;&#x644;&#x645;&#x633;&#x648;&#x642;&#x629;</label>
                                        <div class="form-line">
                                            AJA PHARMACEUTICAL INDUSTRIES
                                        </div>
                                    </div>
                                </div>
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="AtcCode1">&#x643;&#x648;&#x62F; &#x627;&#x644;&#x643;&#x64A;&#x645;&#x64A;&#x627;&#x621; &#x627;&#x644;&#x639;&#x644;&#x627;&#x62C;&#x64A;&#x629; &#x627;&#x644;&#x62A;&#x634;&#x631;&#x64A;&#x62D;&#x64A;&#x629; 1</label>
                                    <div class="form-line">
                                        N06AX26 
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="AtcCode2">&#x643;&#x648;&#x62F; &#x627;&#x644;&#x643;&#x64A;&#x645;&#x64A;&#x627;&#x621; &#x627;&#x644;&#x639;&#x644;&#x627;&#x62C;&#x64A;&#x629; &#x627;&#x644;&#x62A;&#x634;&#x631;&#x64A;&#x62D;&#x64A;&#x629; 2</label>
                                    <div class="form-line">
                                        
                                    </div>
                                </div>
                            </div>
                        </div>
                    </div>
                </div>
        </div>
    </div>
</div>

        </div>
    </div>
    <div id="E-div" class="box-data">
<div class="p-20 text-center font-22">
            <div class="p-10 bg-light-blue  m-t-20 m-b-20 ltr">
                <i class="fa fa-info-circle"></i>&nbsp;
                <span style="font-size: large; background-color: rgb(245,245,245); color: rgb(51,51,51); "> SFDA PIL</span>
                <span style="font-size:small;">  (Patient Information Leaflet (PIL) are under review by Saudi Food and Drug Authority)</span>

            </div>
</div>


<div class="clearfix ltr">
    <div class="col-lg-12 col-md-12 col-sm-12 col-xs-12">
        <div class="clearfix">
            <label class="h2" for="InventedNameEn">1. What this product is and what it is used for</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p><strong>1.&nbsp;&nbsp; </strong><strong>Serious side effects</strong></p><p>Brintellix and other antidepressant medicines may cause serious side effects.</p><p>1. Antidepressant medicines may increase suicidal thoughts or actions in some children, teenagers or young adults within the first few months of treatment.</p><p>2. Depression or other serious mental illnesses are the most important causes of suicidal thoughts or action. Some people may have a particularly high risk of having suicidal thoughts or actions. These include people who have (or have a family history of) bipolar Illness (also called manic-depressive illness) or suicidal thoughts or actions.</p><p>3. How can you watch for and try to prevent suicidal thoughts Actions?</p><p>&bull; Pay close attention to any changes, especially sudden changes in mood, behavior, thoughts, or feelings. This is very important when an antidepressant medicine is started or when the dose is changed,</p><p>&bull; Call your doctor right away to report new or sudden changes in mood, behavior, thoughts or feelings.</p><p>&bull; Keep all follow-up visits with your doctor as scheduled. Call your doctor between visits as needed, especially if you have concerns about symptoms.</p><p>&nbsp;</p><p><strong>2.&nbsp;&nbsp; </strong><strong>What</strong> <strong>Brintellix</strong> <strong>is</strong> <strong>and</strong> <strong>what</strong> <strong>it</strong> <strong>is</strong> <strong>used</strong> <strong>for</strong></p><p>Brintellix contains the active substance vortioxetine. It belongs to a group of medicines called antidepressants.</p><p>Brintellix is used to treat major depressive episodes in adults.</p><p>Brintellix has been shown to reduce the broad range of depressive symptoms, including sadness, inner tension (feeling anxious), sleep, disturbances (reduced sleep), reduced appetite, difficulty in concentrating, feelings of worthlessness, loss of interest in favourite activities, feeling of being slowed down.</p>
            </div>
        </div>
    </div>
    <div class="col-lg-12 col-md-12 col-sm-6 col-xs-12">
        <div class="form-group clearfix">
            <label style="float: left" class="h2" for="PrecautionsEn">2. What you need to know before you use this product</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p><strong>1.&nbsp;&nbsp; </strong><strong>What</strong> <strong>you</strong> <strong>need</strong> <strong>to</strong> <strong>know</strong> <strong>before</strong> <strong>you</strong> <strong>take</strong> <strong>Brintellix</strong></p><p><strong>Do not take Brintellix:</strong></p><p>- if you are allergic to vortioxetine or any of the other ingredients of this medicine (listed in Section 7).</p><p>- if you are taking other medicines known for depression as non-selective monoamine oxidase inhibitors or selective MAO-A inhibitors. Ask your doctor if you are uncertain.</p><p>- Do not take a MAOI within 21 of stopping Brintellix.</p><p>&nbsp;</p><p><strong>Warnings and precautions</strong></p><p>Talk to your doctor or pharmacist before taking Brintellix if you:</p><p>- are taking medicines with a so-called serotonergic effect, such as:</p><p>- tramadol and similar medicines (strong pain killers)</p><p>- sumatriptan and similar medicines with active substance names ending in &ldquo;triptans&rdquo; (used to treat migraine).</p><p>Taking these medicines together with Brintellix may increase the risk of serotonin syndrome.</p><p>This syndrome may be associated with hallucinations, involuntary twitching, accelerated</p><p>heartbeat, high blood pressure, fever, nausea and diarrhoea.</p><p>- have had fits (seizures).</p><p>Your doctor will treat you cautiously if you have a history of fits or have unstable fit</p><p>disorder/epilepsy. Fits are a potential risk with medicines used to treat depression. Treatment</p><p>should be discontinued in any patient who develops fits or where there is an increase in the</p><p>frequency of fits.</p><p>- have had mania</p><p>- have a tendency to bleed or bruise easily, or if you are pregnant (See &lsquo;Pregnancy, breast-feeding and fertility&rsquo;).</p><p>- have low sodium level in the blood.</p><p>- are 65 years of age or older.</p><p>- have a severe kidney disease.</p><p>- have a severe liver disease or a liver disease called cirrhosis.</p><p>- have or previously have had increased pressure in the eye or glaucoma. If your eyes become painful and you develop blurred vision during treatment, contact your doctor.</p><p>-When you are on antidepressant treatment, including vortioxetine, you may also experience feelings of aggression, agitation, anger and irritability. If this occurs, you should talk to your doctor.</p><p><strong>Thoughts of suicide and worsening of your depression</strong></p><p>If you are depressed and/or have anxiety disorders you can sometimes have thoughts of harming or killing yourself. These may be increased when first starting antidepressants, since these medicines all take time to work, usually about two weeks but sometimes longer.</p><p>You may be more likely to think like this if you:</p><p>- have previously had thoughts about killing or harming yourself.</p><p>- are a young adult.</p><p>Information from clinical trials has shown an increased risk of suicidal behaviour in adults aged less than 25 years with psychiatric conditions who were treated with an antidepressant.</p><p>If you have thoughts of harming or killing yourself at any time, contact your doctor or go to a hospital straight away. You may find it helpful to tell a relative or close friend that you are depressed or have an anxiety disorder, and ask them to read this leaflet. You might ask them to tell you if they think your depression or anxiety is getting worse, or if they are worried about changes in your behaviour.</p><p><strong>Children and adolescents</strong></p><p>Brintellix should not be used in paediatric patients (under 18 years of age)because efficacy has not been demonstrated. The safety of Brintellix in children and adolescents aged 7 to 17 years is described in section 5.</p><p>&nbsp;</p><p><strong>Other medicines and Brintellix</strong></p><p>Tell your doctor or pharmacist if you are taking, have recently taken or might take any other</p><p>medicines.</p><p>Tell your doctor if you are taking any of the following medicines:</p><p>- phenelzine, iproniazid, isocarboxazid, nialamide, tranylcypromine (medicines to treat</p><p>depression called non-selective monoamine oxidase inhibitors); you must not take any of these</p><p>medicines together with Brintellix. If you have taken any of these medicines, you will need to</p><p>wait 14 days before you start taking Brintellix.</p><p>After stopping Brintellix, you must allow 14 days before taking any of these medicines:</p><p>- moclobemide (a medicine to treat depression).</p><p>- selegiline, rasagiline (medicines to treat Parkinson&rsquo;s disease).</p><p>- linezolid (a medicine to treat bacterial infections).</p><p>- medicinal products with serotonergic effect e.g. tramadol and similar medicines (strong painkillers) and sumatriptan and similar medicines with active substance names ending in &ldquo;triptans&rdquo; (used to treat migraine). Taking these medicines together with Brintellix may increase the risk of serotonin syndrome (see section warnings and precautions)</p><p>- lithium (a medicine to treat depression and mental disorders) or tryptophan.</p><p>- medicines known to cause low sodium level.</p><p>- rifampicin (a medicine to treat tuberculosis and other infections)</p><p>- carbamazepine, phenytoin (medicines to treat epilepsy or other illness)</p><p>- Warfarin, dipyridamole, phenprocoumon, some antipsychotics, phenothiazines, tricyclic antidepressants, low-dose acetylsalicylic acid and non-steroidal anti-inflammatory drugs (blood thinning medicines and medicines used for pain relief). These may increase bleeding-tendency.</p><p>&nbsp;</p><p>Medicines that increase the risk of fits:</p><p>- sumatriptan and similar medicines with active substance names ending in &ldquo;triptans&rdquo;.</p><p>- tramadol (a strong painkiller).</p><p>- mefloquine (a medicine to prevent and treat malaria).</p><p>- bupropion (a medicine to treat depression also used to wean from smoking).</p><p>- fluoxetine, paroxetine and other medicines to treat depression called SSRI/SNRIs, tricyclics</p><p>- St John&rsquo;s wort (hypericum perforatum) (a medicine to treat depression).</p><p>- quinidine (a medicine to treat heart rhythm disorders).</p><p>- chlorpromazine, chlorprothixene, haloperidol (medicines to treat mental disorders belonging to the group called phenothiazines, thioxanthenes, butyrophenones).</p><p>Please tell your doctor if you are taking any of the medicines above, since your doctor needs to know if you already are at risk for seizure.</p><p>If you are having a urine drug screen, taking Brintellix may cause positive results for methadone when some test methods are used, even though you may not be taking methadone. If this happens, a more specific test can be performed.</p><p><strong>Brintellix with alcohol</strong></p><p>Combining this medicine with alcohol is not advisable.</p><p><strong>Pregnancy, breast-feeding and fertility</strong></p><p>If you are pregnant or breast-feeding, think you may be pregnant or are planning to have a baby, ask your doctor for advice before taking this medicine.</p><p><strong>Pregnancy</strong></p><p>Brintellix should not be used during pregnancy unless the doctor says it is absolutely necessary. If you take medicine to treat depression, including Brintellix, during the last 3 months of your pregnancy, you should be aware that the following effects may be seen in your newborn baby: trouble with breathing, bluish skin, fits, body temperature changes, feeding difficulties, vomiting, low blood sugar, stiff or floppy muscles, vivid reflexes, tremor, jitteriness, irritability, lethargy, constant crying, sleepiness and sleeping difficulties. Contact your doctor immediately if your newborn baby has any of these symptoms.</p><p>Make sure your midwife and/or doctor know you are on Brintellix. When taken during pregnancy, particularly in the last 3 months of pregnancy, medicines like Brintellix may increase the risk of a serious condition in babies, called persistent pulmonary hypertension of the newborn (PPHN), making the baby breathe faster and appear bluish. These symptoms usually begin during the first 24 hours after the baby is born. If this happens to your baby, you should contact your midwife and/or doctor immediately.</p><p>If you take Brintellix near the end of your pregnancy there may be an increased risk of heavy vaginal bleeding shortly after birth, especially if you have a history of bleeding disorders. Your doctor or midwife should be aware that you are taking Brintellix so they can advise you.</p><p><strong>Breast-feeding</strong></p><p>It is expected that the ingredients of Brintellix will pass into breast milk. Brintellix is not to be used during breast-feeding. Your doctor will make a decision on whether you should stop breast-feeding, or stop using Brintellix taking into account the benefit of breast-feeding for your child, and the benefit of therapy for you.</p><p>&nbsp;</p><p><strong>Driving and using machines</strong></p><p>Brintellix has no or negligible influence on the ability to drive and use machines. However, as adverse reactions such as dizziness have been reported, caution is advised during such activities when beginning Brintellix treatment or changing the dose.</p><p>Brintellix contains Sodium</p><p>This medicine contains less than 1 mmol sodium (23 mg) per tablet, that is to say essentially &lsquo;sodium-free&rsquo;.</p>
            </div>
        </div>
    </div>
    <div class="col-lg-12 col-md-12 col-sm-6 col-xs-12">
        <div class="clearfix">
            <label class="h2" for="AdministrationRoutesEn">3. How to use this product.</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p><strong>1.&nbsp;&nbsp; </strong><strong>H</strong><strong>o</strong><strong>w to take Brintellix</strong></p><p>Always take this medicine exactly as your doctor has told you. Check with your doctor or pharmacist if you are not sure.</p><p>The recommended dose of Brintellix is 10 mg vortioxetine taken once daily dose in adults less than 65 years of age. The dose may be increased by your doctor to a maximum of 20 mg vortioxetine per day or lowered to a minimum of 5 mg vortioxetine per day depending on your response to treatment.</p><p>For Elderly people 65 years of age or older the starting dose is 5 mg vortioxetine taken once daily.</p><p><strong>Method of administration</strong></p><p>Take one tablet with a glass of water.</p><p>The tablet can be taken with or without food.</p><p><strong>D</strong><strong>uration of treatment</strong></p><p>Take Brintellix for as long as your doctor recommends.</p><p>Continue to take Brintellix even if it takes some time before you feel any improvement in your condition.</p><p>Treatment should be continued for at least 6 months after you feel well again.</p><p><strong>I</strong><strong>f you take more Brintellix than you should</strong></p><p>If you take more than the prescribed dose of Brintellix, contact your doctor or nearest hospital emergency department immediately. Have the container and any remaining tablets available. Do this even if there are no signs of discomfort. Overdose signs could be dizziness, nausea, diarrhoea, stomach discomfort, itching of the whole body, sleepiness and flushing.</p><p>Following intake of dosages several times higher than the prescribed dose, fits (seizures) and a rare condition called serotonin syndrome have been reported.</p><p>&nbsp;</p><p><strong>I</strong><strong>f you forget to take Brintellix</strong></p><p>Take the next dose at the usual time. Do not take a double dose to make up for a forgotten dose.</p><p><strong>I</strong><strong>f you stop taking Brintellix</strong></p><p>Do not stop taking Brintellix without talking with your doctor.</p><p>Your doctor may decide to reduce your dose before you finally stop taking this medicine.</p><p>Some patients who stop taking Brintellix have experienced symptoms such as dizziness, headache, tingling feelings like pins and needles or electric shock-like feelings (particularly in the head), inability to sleep, feeling sick or vomiting, feeling anxious, irritable or agitated, feeling tired or shaking. These symptoms may occur within the first week after stopping Brintellix.</p><p>If you have any further questions on the use of this medicine, ask your doctor or pharmacist.</p><p>&nbsp;</p>
            </div>
        </div>
    </div>
    <div class="col-lg-12 col-md-12 col-sm-6 col-xs-12">
        <div class="clearfix">
            <label class="h2" for="SideEffectsEn">4. Possible side effects</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p><strong>1.&nbsp;&nbsp; </strong><strong>P</strong><strong>ossible side effects</strong></p><p>Like all medicines, this medicine can cause side effects, although not everybody gets them. In general, the observed side effects were mild to moderate and occurred within the first two weeks of treatment. The reactions were usually temporary and did not lead to cessation of therapy.</p><p>Side effects listed below have been reported in the following frequencies.</p><p>Very common: may affect more than 1 in 10 people</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; nausea</p><p>Common: may affect up to 1 in 10 people</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; diarrhoea, constipation, vomiting</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; dizziness</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; itching of the whole body</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; abnormal dreams</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; increased sweating</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; indigestion</p><p>Uncommon: may affect up to 1 in 100 people</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; flushing</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; night sweats</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; blurred vision</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; involuntary shaking (tremor)</p><p>Rare: may affect up to 1 in 1,000 people</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; enlarged pupils (mydriasis), which can increase the risk of glaucoma (see section 3)</p><p>Not known: frequency cannot be estimated from available data</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; low levels of sodium in the blood (the symptoms may include feeling dizzy, weak, confused, sleepy or very tired, or feeling or being sick; more serious symptoms are fainting, fits or falls)</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; serotonin syndrome (see section 3)</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; allergic reactions, that may be serious, causing swelling of the face, lips, tongue or throat, difficulties breathing or swallowing, and/or a sudden drop in blood pressure (making you feel dizzy or lightheaded)</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; hives</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; excessive or unexplained bleeding (including bruising, nose bleeding, gastrointestinal and</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; vaginal bleeding)</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; rash</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; sleep disorders (insomnia)</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; agitation and aggression. If you experience these side effects, contact your doctor (see section 3).</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; headache</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; increase in a hormone called prolactin in the blood</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; a constant urge to move (akathisia)</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; grinding one&rsquo;s teeth (bruxism)</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; inability to open your mouth (lockjaw/trismus)</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; restless leg syndrome (urges to move the legs to stop painful or odd sensations, often occuring at night)</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; abnormal milky discharge from the breast (galactorrhoea)</p><p>An increased risk of bone fractures has been observed in patients taking this type of medicines.</p><p>An increased risk of sexual dysfunction has been reported with the 20 mg dose, and in some patients this side effect was observed at lower doses.</p><p><strong>Additional side effects in children and</strong><strong> adolescents</strong></p><p>Side effects observed with vortioxetine in children and<strong> </strong>adolescents were similar to those seen for adults except for abdominal pain related events that were observed more often than in adults and suicidal thoughts that were observed more often in adolescents than in adults.</p><p><strong>Reporting of side effects</strong></p><p>If you get any side effects, talk to your doctor or pharmacist. This includes any possible side effects not listed in this leaflet.</p><p>By reporting side effects, you can help provide more information on the safety of this medicine.</p>
            </div>
        </div>
    </div>
    <div class="col-lg-12 col-md-12 col-sm-6 col-xs-12">
        <div class="clearfix">
            <label class="h2" for="StorageConditionsEn">5. How to store this product</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p>Keep this medicine out of the sight and reach of children.</p><p>Do not use this medicine after the expiry date that is stated on the packaging after EXP. The expiry date refers to the last day of that month.</p><p>Do not store above 30 &deg;C.</p><p>Do not throw away any medicines via wastewater or household waste. Ask your pharmacist how to throw away medicines you no longer use. These measures will help to protect the environment.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <label style="float: left">6. Further information</label>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="IngredientsEn">a. What this product contains</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p><strong>What Brintellix contains</strong></p><p><strong>10 mg:</strong></p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; The active substance is vortioxetine. Each film-coated tablet contains 10 mg vortioxetine (ashydrobromide).</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; The other ingredients are mannitol (E421), microcrystalline cellulose, hydroxypropylcellulose, sodium starch glycolate (type A), magnesium stearate, hypromellose, Macrogol 400, titanium dioxide (E171), iron oxide yellow (E172).</p><p>&nbsp;</p><p><strong>20 mg:</strong></p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; The active substance is vortioxetine. Each film-coated tablet contains 20 mg vortioxetine (as hydrobromide).</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; The other ingredients are mannitol (E421), microcrystalline cellulose, hydroxypropylcellulose, sodium starch glycolate (type A), magnesium stearate, hypromellose, Macrogol 400, titanium dioxide (E171), iron oxide red (E172).</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="ShapeAndContentsEn">b. What this product looks like and contents of the pack</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                What Brintellix looks like and contents of the pack
10 mg:
Yellow, almond-shaped 5 x 8.4 mm film-coated tablets marked with “TL” on one side and “10” on the other side.
20 mg:
Red, almond-shaped 5 x 8.4 mm film-coated tablet marked with “TL” on one side and “20” on the other side.
Brintellix film-coated tablets 10 mg and 20 mg are available in blister packs of 14 and 28. Not all strengths or pack sizes may be marketed.
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="ManufacturingAndMarketingEn">c. Marketing Authorization Holder and Manufacturer</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p><strong>Marketing Authorisation Holder and Manufacturer</strong></p><p><strong>Marketing Authorisation Holder:</strong></p><p>AJA Pharmaceutical Industries Co, Ltd.</p><p>Hail, Saudi Arabia</p><p>&nbsp;</p><p><strong>Manufacturer:</strong></p><p>H. Lundbeck A/S</p><p>Ottiliavej 9</p><p>2500 Valby</p><p>Denmark</p><p>&nbsp;</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="RevisionNoteEn">d. This leaflet was last revised in {MM/YYYY}</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                d. This leaflet was last revised in: February 2024	
            </div>
        </div>
    </div>
</div>    </div>
    <div id="A-div" class="box-data">
<div class="p-20 text-center font-22">
            <div class="p-10 bg-light-blue  m-t-20 m-b-20 ltr">
                <i class="fa fa-info-circle"></i>&nbsp;
                <span style="font-size: large; background-color: rgb(245,245,245); color: rgb(51,51,51); "> نشرة الدواء تحت مراجعة الهيئة العامة للغذاء والدواء</span>
                <span style="font-size:small;">  (اقرأ هذه النشرة بعناية قبل البدء في استخدام هذا المنتج لأنه يحتوي على معلومات مهمة لك)</span>
            </div>
    <div class="p-10 bg-light-blue font-15 m-t-20 m-b-20 ltr">

    </div>

</div>
<div class="clearfix rtl">
    <div class="col-xs-12">
        <div class="form-group clearfix">
            <label class="h2" for="InventedNameAr">1. ما ھو هذا المستحضر وماھي دواعي استعماله</label>
        </div>
        <div class="form-group clearfix" style="float: right">
            <br />
            <p dir="RTL"><strong>1.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; </strong><strong>الآثار الجانبية الخطيرة</strong></p><p dir="RTL">&nbsp;</p><p dir="RTL">قد يُؤدي تناوُل عقار برينتيليكس مع مضادات الاكتئاب الأخرى إلى آثار جانبية خطيرة.</p><ol><li dir="RTL">قد تزيد الأدوية المُضادَّة للاكْتِئاب من الأفعال أو الأفكار الانتحارية لدى بعض الأطفال والمراهقين وصغار البالغين خلال الأشهر الأولى القليلة من العلاج.</li></ol><p dir="RTL">2.&nbsp;&nbsp;&nbsp;&nbsp; يُعَد الاكتئاب وأمراض نفسية خطيرة أخرى أهم أسباب الأفعال والأفكار الانتحارية.</p><p dir="RTL">قد يكون لدى بعض الأشخاص مخاطرة عالية خاصَّة للأفعال أو الأفكار الانتحارية. ومن بينهم الأشخاص المصابون (أو لديهم تاريخ عائلي) بمرض ذي اتجاهين (يُسمى أيضًا مرضًا هَوَسِيًّا اكْتِئابِيًّا) أو أفعال أو أفكار انتحارية.</p><p dir="RTL">3.&nbsp;&nbsp;&nbsp;&nbsp; كيف يُمكِنك مراقبة ومحاولة منع الأفكار والأفعال الانتحارية؟</p><p dir="RTL">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; &middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; أعط اهتمامًا كبيرًا لأي تغييرات، خاصَّة التغييرات المفاجئة، في المزاج أو الأسلوب أو الأفكار أو الشعور. فهذا مهم جدًّا عندما يتم بدء تناول دواء مضاد للاكتئاب أو عند تغيير الجرعة.</p><p dir="RTL">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; &middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; اتصل بموفر الرِّعاية الصِّحية مباشرة لإبلاغه بتغييرات جديدة أو مفاجئة في المزاج أو الأسلوب أو الأفكار أو الشعور.</p><p dir="RTL">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; &middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; التزم بحضور جميع زيارات المتابعة مع طبيبك وفقًا للجدول. إذا لزم الأمر، اتصل بطبيبك بين الزيارات، خاصَّة إذا كانت لديك مخاوف متعلقة بالأعراض.</p><p dir="RTL"><strong>1.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; </strong><strong>ما هو عقار برينتيليكس؟ وفيمَ يُستَخدَم؟</strong></p><p dir="RTL">يحتوي عقار برينتيليكس على المادة الفعّالة فورتيوكسيتين. وينتمي هذا الدَّواء إلى مجموعة أدوية تُسمى مضادات الاكتئاب ولقد تم وصفه لك من أجل علاج الاكتئاب الذي تعاني منه.</p><p dir="RTL">قد أظهر عقار برينتيليكس أنه يحد من أعراض الاكتئاب الكثيرة، والتي من بينها: الحزن، والتَّوتر الدَّاخلي (الشعور بالقلق)، واضطرابات النوم (قلة النوم)، ونقص الشهية، وصعوبة التركيز، والشعور بانعدام القيمة وفقدان الاهتمام بالأنشطة المفضلة، والشعور بالتباطؤ.</p><p dir="RTL">يُستخدم عقار برينتيليكس لعلاج نوبات الاكتئاب الكبرى في البالغين.</p>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="form-group clearfix">
            <label class="h2" for="PrecautionsAr">2. ما الذي يجب عليك معرفته قبل استعمال هذا المستحضر</label>
        </div>
        <div class="m-r-60">
            <p dir="RTL"><strong>1.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; </strong><strong>ما تحتاج إلى معرفته قبل تناوُل عقار برينتيليكس</strong></p><p dir="RTL"><strong>كيفية تناول عقار برينتيليكس</strong><strong>:</strong></p><p dir="RTL">-إذا كنت تعاني من حساسية تجاه فورتيوكسيتين أو أي من المكونات الأخرى بهذا الدواء (المدرجة في القسم 7 )</p><p dir="RTL">- إذا كنت تتناول أدوية أخرى معروفة لعلاج الاكتئاب مثل مثبطات أوكسيديز أحادي الأمين غير الانتقائية</p><p dir="RTL">&nbsp;أو مثبطات أوكسيديز<em> </em>أحادي الأمين-أ الانتقائية. استشر طبيبك إذا لم تكن متأكدا من كيفية التناول.</p><p dir="RTL">لا تأخذ مثبطات أوكسيديز أحادي الأمين&nbsp; خلال 21 يوم من إيقاف تناول&nbsp; دواء برنتليكس-</p><p dir="RTL"><strong>تحذيرات واحتياطات</strong></p><p dir="RTL">تحدث إلى طبيبك أو الصيدلي الخاص بك قبل تناول عقار <strong>برينتيليكس في الحالات التالية</strong>:</p><p dir="RTL">- إذا كنت تتناول أدوية لها ما يُعرف باسم التأثير السيروتونيني، مثل:</p><p dir="RTL">- ترامادول وأدوية مماثلة (مسكنات قوية للآلام)</p><p dir="RTL">-عقار سوماتريبتان وأدوية مماثلة بها مواد فعّالة تنتهي أسماؤها بالمقطع &quot;تريبتان&quot; (تستخدم لعلاج الصداع النصفي).</p><p dir="RTL">قد يزيد تناوُل هذه الأدوية بالتزامن مع عقار برينتيليكس من خطر الإصابة بمتلازمة السيرُوتُونين.</p><p dir="RTL">قد تكون هذه المتلازمة مصحوبة بالهلاوس، الانتفاض العضلي اللا إرادي،</p><p dir="RTL">&nbsp;ضربات قلب متسارعة، ارتفاع ضغط الدم، حمى، غثيان وإسهال.</p><p dir="RTL">- إذا كنت قد أصبت بنوبات (نوبات تشنجية).</p><p dir="RTL">سوف يعاملك طبيبك بحذر إذا كان لديك تاريخ من الإصابة بنوبات تشنجية أو لديك اضطراب نوبة غير مستقرة</p><p dir="RTL">/الصرع. تُعد النوبات التشنجية خطرًا محتملًا مع الأدوية المستخدمة لعلاج الاكتئاب.</p><p dir="RTL">&nbsp;يجب وقف العلاج في أي مريض يصاب بالنوبات أو عندما يكون هناك زيادة في</p><p dir="RTL">معدّل تكرار حدوث النوبات.</p><p dir="RTL">- إذا كنت قد أصبت بهوس</p><p dir="RTL">- إذا كان لديك قابلية لحدوث النزيف أو التعرض لكدمات بسهولة أو إذا كنت حاملاً . (انظر قسم : الحمل والرَّضاعة الطبيعية والخصوبة)</p><p dir="RTL">- إذا كان لديك انخفاض في مستوى الصوديوم في الدَّم.</p><p dir="RTL">- المرضى الذين تبلغ أعمارهم 65 عامًا أو أكثر</p><p dir="RTL">- إذا كنت تُعاني من مرض كلوي شديد.</p><p dir="RTL">- إذا كنت تُعاني من مرض شديد بالكبد أو مرض كبدي يسمى تليف الكبد</p><p dir="RTL">- من كان لديهم أو سبق لهم التعرض لزيادة الضغط في العين أو الجلوكوما. إذا أصبحت عينيك مؤلمة وحدث تشوش في الرؤية أثناء العلاج ، اتصل بطبيبك.</p><p dir="RTL">عندما يكون لديك علاج مضاد للاكتئاب ، بما في ذلك فورتيوكسيتين ، قد تواجه أيضًا مشاعر العدوان والهياج والغضب والتهيج. إذا حدث هذا ، يجب عليك التحدث مع طبيبك.</p><p>&nbsp;</p><p dir="RTL"><strong>الأفكار الانتحارية وتفاقم الاكتئاب لديك</strong></p><p dir="RTL">إذا كنت مكتئبًا و/أو تعاني من اضطرابات القلق، قد تخطر لك أحيانًا أفكار بإيذاء أو قتل نفسك. قد تزداد هذه الأفكار عند بدء العلاج بمضادات الاكتئاب إذ تستغرق جميع هذه الأدوية وقتًا لتؤدي مفعولها، وتستغرق عادة نحو أسبوعين لكن تستغرق أحيانًا وقتًا أطول.</p><p dir="RTL">يرجح أن هذه الأفكار ستطرأ لك في الحالات التالية:</p><p dir="RTL">- إذا كانت قد طرأت لك من قبل أفكار بقتل أو إيذاء نفسك</p><p dir="RTL">- إذا كانت بالغًا يافعًا.</p><p dir="RTL">أظهرت المعلومات من التجارب السريرية تزايد خطر السلوك الانتحاري في البالغين الذين تقل أعمارهم عن 25 عامًا ممن يعانون من مشكلات نفسية ويُعالجون بمضادات اكتئاب.</p><p dir="RTL">إذا<strong> </strong>طرأت<strong> </strong>لك<strong> </strong>أفكار<strong> </strong>بإيذاء<strong> </strong>أو<strong> </strong>قتل<strong> </strong>نفسك<strong> </strong>بأي<strong> </strong>وقت،<strong> </strong>اتصل<strong> </strong>بطبيبك<strong> </strong>أو<strong> </strong>اقصد<strong> </strong>مستشفى<strong> </strong>في<strong> </strong>الحال<strong>.</strong> قد تجد أن إخبار أحد أقاربك أو إخبار صديق مقرب بأنك تعاني من الاكتئاب أو اضطرابات القلق مفيدًا، واطلب منه قراءة هذه النشرة. يمكنك أن تطلب منهم إخبارك إذا كانوا يرون أن الاكتئاب أو القلق الذي تعاني منه يزداد سوءًا، أو إذا كانوا يشعرون بالقلق حيال تغيرات في سلوكك.</p><p dir="RTL"><strong>الأطفال والمراهقون</strong></p><p>لا ينبغي استخدام برينتيليكس في مرضى الأطفال )أقل من 18 عامًا ) لأنه لم يتم إثبات فعاليتها. تم وصف سلامة برينتيليكس عند الأطفال والمراهقين الذين تتراوح أعمارهم بين 7 إلى 17 عامًا (انظر قسم: 5).</p><p dir="RTL"><strong>&nbsp;</strong></p><p dir="RTL"><strong>&nbsp;</strong></p><p dir="RTL"><strong>تناوُل أدوية أخرى مع عقار برينتيليكس</strong></p><p dir="RTL">أخبر طبيبك أو الصيدلي الخاص بك إذا كنت تتناول أو تناولت مؤخرًا أو قد تتناول أي أدوية أخرى،</p><p dir="RTL">أخبر طبيبك إذا كنت تتناول أيًّا من الأدوية التَّالية:</p><p dir="RTL">فينلزين،إبرونيازيد, أيزوكاربوكسازيد, نيالاميد, ترانيلسيبرومين (من الأدوية المستخدمة لعلاج الاكتئاب</p><p dir="RTL">&nbsp;تُسمى مثبطات أوكسيديز أحادي الأمين غير الانتقائية)</p><p dir="RTL">&nbsp;يجب عليك عدم تناوُل أيًا من هذه الأدوية بالتزامن مع عقار برينتيليكس. إذا كنت قد تناولت أيًّا من هذه الأدوية، فسينبغي عليك أن تنتظر لمدة 14 يومًا قبل أن تبدأ في تناول عقار برينتيليكس.</p><p dir="RTL">&nbsp;بعد التَّوقف عن تناول عقار برينتيليكس، يجب أن تنتظر لمدة 14 يومًا قبل أن تتناول أيًّا من هذه الأدوية</p><p dir="RTL">-عقار موكلوبيميد (دواء يُستخدم لعلاج الاكتئاب).</p><p dir="RTL">-عقار سيلجيلين، عقار راساجيلين (الأدوية المستخدمة لعلاج مرض الشلل الرعَّاش (مرض باركنسون)).</p><p dir="RTL">-عقار لينيزوليد (دواء يُستخدم لعلاج العدوى البكتيرية).</p><p dir="RTL">-عقار ليثْيُوم (دواء يُستخدم لعلاج الاكتئاب والاضطرابات النفسية) أو عقار تريبتوفان.</p><p dir="RTL">- المنتجات الطبية مع تأثير هرمون السيروتونين ، على سبيل المثال. ترامادول وأدوية مماثلة (مسكنات قوية للألم) وسوماتريبتان وأدوية مماثلة لها أسماء مواد فعالة تنتهي بـ &quot;تريبتان&quot; (تستخدم لعلاج الصداع النصفي). قد يؤدي تناول هذه الأدوية مع برينتيليكس إلى زيادة خطر الإصابة بمتلازمة السيروتونين (انظر قسم التحذيرات والاحتياطات).</p><p dir="RTL">-أدوية معروف أنها تُؤدي إلى انخفاض مستوى الصوديوم.</p><p dir="RTL">-عقار رِيفامبيسِين (دواء يُستخدم لعلاج السُل وعدوى أخرى).</p><p dir="RTL">-عقار كَرْبامازِيبين، عقار فينيتوين (من الأدوية المستخدمة لعلاج الصرع أو أمراض أخرى).</p><p dir="RTL">-عقار وارفارين، عقار ديبيريدامول، عقار فينوبروكومون،بعض مضادات الذهان، الفينوثيازينات، مضادات الاكتئاب ثلاثية الحلقات، حمض أسيتيل الساليسيليك بجرعة منخفضة والأدوية المضادة للالتهابات غير الستيرويدية (أدوية تسييل الدم والأدوية المستخدمة لتخفيف الآلام) &nbsp;هذه قد تزيد من&nbsp; نَزْعة النزيف.</p><p dir="RTL">أدوية ترفع من خطر احتمالية حدوث نوبات تشنجية :</p><p dir="RTL">-عقار سوماتريبتان وأدوية مماثلة بها مواد فعّالة تنتهي أسماؤها بالمقطع &quot;تريبتان&quot;.</p><p dir="RTL">-ترامادول (مسكن قوي للألم).</p><p dir="RTL">-عقار ميفْلوكِين (دواء يُستخدم للوقاية من الملاريا وعلاجها).</p><p dir="RTL">-عقار بُوبْرُوبْيُون (دواء يستخدم لعلاج الاكتئاب كما يستخدم للمساعدة في الإقلاع عن التدخين).</p><p dir="RTL">-عقار فلوكستين وعقار باروكسيتين وأدوية أخرى مستخدمة لعلاج الاكتئاب تُسمى مثبطات امتصاص السيرُوتُونين الانتقائية/مثبطات إعادة امتصاص السيروتونين-النورإيبينفرين، والأدوية ثلاثية الحلقات.</p><p dir="RTL">-نبتة سانت جونز (عشبة هايبريكوم برفوراتام) (تستخدم كدواء لعلاج الاكتئاب).</p><p dir="RTL">-عقار كينيدين (دواء يُستخدم لعلاج اضطرابات نظم القلب).</p><p dir="RTL">-عقار كلُوربرُومازين، عقار كلُوربرُوتِيكْسِين، عقار هالُوبِيرِيدُول (أدوية تُستخدم لعلاج الاضطرابات النفسية وتنتمي إلى مجموعات تُسمى الفينوثيازينات، الثّيُوزانثينات، البُّوتيرُوفينونات).</p><p dir="RTL">يُرجى إخبار طبيبك إذا كنت تتناول أيًّا من الأدوية المذكورة أعلاه، حيث ينبغي أن يعرف طبيبك ما إذا كنت معرضًا بالفعل لخطورة الإصابة بنوبة تشنجية.</p><p dir="RTL">إذا كان لديك تحليل المخدرات في البول ، فقد يؤدي تناول برينتيليكس إلى نتائج إيجابية للميثادون عند استخدام بعض طرق الاختبار ، على الرغم من أنك قد لا تتناول الميثادون. إذا حدث ذلك ، يمكن إجراء اختبار أكثر تحديدًا.</p><p dir="RTL">&nbsp;</p><p dir="RTL"><strong>تناول عقار برينتيليكس مع الكحوليات</strong></p><p dir="RTL">لا ينصح بالجمع بين هذا الدَّواء والكحول.</p><p dir="RTL"><strong>الحمل والرَّضاعة الطبيعية والخصوبة</strong></p><p dir="RTL">إذا كنتِ حاملًا أو مرضعًا، أو تعتقدين أنكِ حامل أو تخططين لذلك، فاستشيري طبيبك قبل تناوُل هذا الدَّواء.</p><p dir="RTL">&nbsp;</p><p dir="RTL"><strong>الحمل</strong></p><p dir="RTL">لا يجب استخدام عقار برينتيليكس أثناء الحمل، إلا إذا رأى الطبيب أنه من الضروري للغاية استخدامه. إذا تناولتِ أدوية لعلاج الاكتئاب، من بينها عقار برينتيليكس، خلال الثلاثة أشهر الأخيرة من الحَمْل، فيجب أن تدركي أن طفلك حديث الولادة قد يعاني من الآثار التَّالية: صعوبة التَّنفس وازرقاق الجلد، ونوبات تشنجية وتغييرات في درجة حرارة الجسم وصعوبات في التغذية وقيء وانخفاض مستوى السكر في الدَّم وتيبس العضلات أو ترهلها وانعكاسات حية وارتعاش وعصبية وهياج وخمول وبكاء مستمر ونُعاس وصعوبات في النوم. اتصلي بطبيبك على الفور إذا عانى طفلك حديث الولادة من أي من هذه الأعراض.</p><p dir="RTL">احرصي على إخبار ممرضة التوليد و/أو طبيبك بأنك تتناولين عقار برينتيليكس. في حالة تناول أدوية مثل عقار برينتيليكس أثناء الحمل، خاصة في آخر 3 شهور من الحمل، فقد تزيد خطورة تعرض الأطفال لحالة خطيرة، تُسمى ارتفاع الضغط الرئوي المستمر لحديثي الولادة، مما يجعل الطفل يتنفس بشكل أسرع ويبدو أزرق اللون. تبدأ هذه الأعراض عادة في غضون الـ 24 ساعة الأولى بعد ولادة الطفل. إذا حدث هذا لطفلِك، يجب عليكِ الاتصال بممرضة التوليد الخاصة بك و/أو طبيبك على الفور.</p><p dir="RTL">إذا كنتي تتناولين برينتيليكس بالقرب من نهاية الحمل ، فقد يكون هناك خطر متزايد من حدوث نزيف مهبلي حاد بعد الولادة بفترة وجيزة ، خاصة إذا كان لديك تاريخ من اضطرابات النزيف. يجب أن يكون طبيبك أو ممرضة التوليد على علم بأنك تتناول برينتيليكس حتى يتمكنوا من تقديم النصح لك.</p><p dir="RTL">&nbsp;</p><p dir="RTL"><strong>الرَّضاعة الطبيعية</strong></p><p dir="RTL">يتوقع أن تفرز مكونات عقار برينتيليكس في لبن الأم. لا يجب استخدام عقار برينتيليكس أثناء الرضاعة الطبيعية. سيقرر طبيبك ما إذا كان يجب أن تتوقفي عن الرضاعة الطبيعية، أو أن تتوقفي عن تناول عقار برينتيليكس مع الأخذ بعين الاعتبار فوائد الرضاعة الطبيعية بالنسبة لطفلك، وفوائد العلاج بالنسبة لكِ.</p><p dir="RTL"><strong>القيادة واستخدام الآلات</strong></p><p dir="RTL">ليس لعقار برينتيليكس تأثير أو هناك تأثير لا يكاد يذكر في القدرة على القيادة واستخدام الآلات. ومع ذلك، نظرًا لأنه تم الابلاغ عن حدوث آثار جانبية مثل الدوخة يُوصى بتوخي الحذر خلال القيام بأنشطة مثل هذه عند بدء العلاج بعقار برينتيليكس أو عند تغيير الجرعة.</p><p><strong>يحتوي برينتيليكس على الصوديوم</strong></p><p dir="RTL">يحتوي هذا الدواء على أقل من 1 ملي مول صوديوم ( 23 مجم) لكل قرص ، أي بشكل أساسي &quot;خالٍ من الصوديوم&quot;.</p><p>&nbsp;</p><p dir="RTL"><strong>&nbsp;</strong></p>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            https://localhost:44358/Dashboard
            <label class="h2" for="AdministrationRoutesAr">3. ماھي طريقة استعمال هذا المستحضر</label>
        </div>
        <div class="m-r-60">
            <p dir="RTL"><strong>1.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; </strong><strong>كيفية تناول عقار برينتيليكس</strong></p><p dir="RTL">تناول دائما هذا الدَّواء كما أخبرك طبيبك بالضبط. يُرجى مراجعة طبيبك أو الصيدلي الخاص بك إذا لم تكن متأكدًا من كيفية الاستخدام.</p><p dir="RTL">الجرعة الموصى بها من عقار برينتيليكس هي 10 ملجم فورتيوكسيتين يتم تناولها مرة واحدة يوميًّا في البالغين الأقل من 65 عامًا.</p><p dir="RTL">&nbsp;قد يقوم طبيبك بزيادة الجرعة إلى الجرعة القصوى البالغة 20 ملجم فورتيوكسيتين في اليوم أو تقليلها إلى أدنى جرعة تبلغ 5 ملجم فورتيوكسيتين في اليوم وذلك بحسب مدى استجابتك للعلاج.</p><p dir="RTL">بالنسبة للمرضى من كبار السن الذين يبلغون من العُمْر 65 عامًا أو أكثر تكون جرعة البدء 5 ملجم فورتيوكسيتين يتم تناوُلها مرَّة واحدة يوميًّا.</p><p>&nbsp;</p><p dir="RTL"><strong>طريقة التَّناول</strong></p><p dir="RTL">تناول قرصًا واحدًا مع كوب من الماء.</p><p dir="RTL">يمكن تناول العقار بطعام أو بدون.</p><p>&nbsp;</p><p dir="RTL"><strong>مدة العلاج</strong></p><p dir="RTL">تناول عقار برينتيليكس للمدة التي يوصي طبيبك بها.</p><p dir="RTL">استمر في تناول عقار برينتيليكس حتى إذا استغرق بعض الوقت لتشعر بأي تحسن في حالتك.</p><p dir="RTL">يجب أن يستمر العلاج لمدة لا تقل عن 6 أشهر بعد أن تشعر بتحسن من جديد.</p><p>&nbsp;</p><p dir="RTL"><strong>إذا تناولت كمية من عقار برينتيليكس أكثر مما يجب</strong></p><p dir="RTL">إذا تناولت جرعة من عقار برينتيليكس أكثر من الموصوفة لك، فاتصل بطبيبك أو بقسم الطَّوارئ بأقرب مستشفى على الفور. خذ العلبة وأية أقراص متبقية موجودة معك. افعل ذلك حتى إذا لم تكن هناك أية علامات غير مريحة. قد تكون علامات تناول جرعة زائدة: الدّوخَة، والغثيان، والإسهال، واضطراب المعدة، وحكة بالجسم بالكامل، ونعاس، واحمرار الجلد.</p><p>&nbsp;</p><p dir="RTL"><strong>إذا أغفلت تناول عقار برينتيليكس</strong></p><p dir="RTL">قم بتناول الجرعة التَّالية في الوقت المحدد. لا تتناول جرعة مضاعفة لتعويض جرعة أغفلتها.</p><p>&nbsp;</p><p dir="RTL"><strong>إذا توقفت عن تناول عقار برينتيليكس</strong></p><p dir="RTL">لا تتوقف عن تناول عقار برينتيليكس قبل استشارة طبيبك.</p><p dir="RTL">قد يقرر طبيبك تقليل جرعتك قبل أن تتوقف أخيرًا عن تناول هذا الدواء.</p><p dir="RTL">عانى بعض المرضى الذين توقفوا عن تناول برينتيليكس من أعراض مثل الدوخة والصداع والشعور بالوخز مثل الدبابيس والإبر أو مشاعر تشبه الصدمة الكهربائية (خاصة في الرأس) ،عدم القدرة على النوم ، الشعور بالمرض أو القيء ،الشعور بالقلق ،سرعة الانفعال أو الانفعال ، الشعور بالتعب أو الاهتزاز. قد تحدث هذه الأعراض في غضون الأسبوع الأول بعد التوقف عن برينتيليكس</p><p dir="RTL">إذا كانت لديك أية أسئلة إضافية حول استخدام هذا الدَّواء، فاستشر الطبيب أو الصيدلي الخاص بك.</p><p dir="RTL">&nbsp;</p>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            <label class="h2" for="SideEffectsAr">4. الأعراض الجانبية المحتملة</label>
        </div>
        <div class="m-r-60">
            <p dir="RTL"><strong>الآثار الجانبية المحتملة</strong></p><p dir="RTL">&nbsp;</p><p dir="RTL">مثله مثل كافة الأدوية، قد يُسبب هذا الدَّواء آثار جانبية، على الرَّغم من عدم حدوثها لدى الجميع. بصفة عامة، كانت الآثار الجانبية التي لوحظت خفيفة إلى معتدلة وحدثت خلال أول أسبوعين من العلاج. عادةً ما كانت التفاعلات مؤقتة ولم تؤد إلى وقف العلاج.</p><p dir="RTL">تم الإبلاغ عن الآثار الجانبية المُدرجة أدناه بمعدلات التكرار التالية.</p><p dir="RTL">شائعة جدًّا: <em>قد تُؤثر على أكثر من شخص واحد من بين كل </em><em>10&nbsp;</em><em>أشخاص</em></p><p dir="RTL">غثيان.</p><p dir="RTL">شائعة: <em>قد تُؤثر على ما يصل إلى شخص واحد من بين كل </em><em>10&nbsp;</em><em>أشخاص</em><em>.</em></p><p dir="RTL">إسهال، إمساك، قيء.</p><p dir="RTL">دوخة؛</p><p dir="RTL">- حكة بالجسم بالكامل.</p><p dir="RTL">- أحلام غير طبيعية</p><p dir="RTL">- زيادة التعرق</p><p dir="RTL">- عسر الهضم</p><p dir="RTL">&nbsp;</p><p dir="RTL">غير شائعة: <em>قد تُؤثر على ما يصل إلى شخص واحد من بين كل </em><em>100 </em><em>شخص</em></p><p dir="RTL">-احمرار الجلد</p><p dir="RTL">-تعرق ليلي.</p><p dir="RTL">-عدم وضوح الرؤية</p><p dir="RTL">- اهتزاز لا إرادي (رعاش)</p><p dir="RTL">&nbsp;</p><p dir="RTL">نادرة: <em>قد تظهر لدى 1 من كل 1000 شخص</em></p><p dir="RTL">&nbsp;- تضخم حدقة العين (توسع حدقة العين) ، والتي يمكن أن تزيد من خطر الإصابة بالجلوكوما (انظر القسم 3)</p><p dir="RTL">&nbsp;</p><p dir="RTL">غير معروفة: لا يمكن تقدير معدل التكرار من واقع البيانات المتاحة</p><p dir="RTL">انخفاض مستويات الصوديوم في الدم (قد تشمل الأعراض :الشعور بالدوخة أو الضعف أو الارتباك أو النعاس أو التعب الشديد أو الشعور بالإعياء أو الإعياء، وتتمثل الأعراض الأكثر خطورة في الإغماء أو النوبات التشنجية أو الغشي)،</p><p dir="RTL">متلازمة السيرُوتُونين (انظر قسم: 3)</p><p dir="RTL">- تفاعلات حساسية، قد تكون خطيرة، وتسبب تورم بالوجه أو الشفتين أو اللسان أو الحلق، وصعوبات في التنفس أو البلع، و/ أو هبوط مفاجئ في ضغط الدم (مما يجعلك تشعر بدوخة أو دوار)</p><p dir="RTL">شرى (أرتكاريا)</p><p dir="RTL">- فرط النزيف أو نزيف غير مبرر (بما في ذلك الكدمات ونزيف من الأنف والجهاز الهضمي و النزيف المهبلي)</p><p dir="RTL">-طفح جلدي</p><p dir="RTL">- اضطرابات النوم (الأرق)</p><p dir="RTL">- الهياج والعدوان. إذا واجهت هذه الآثار الجانبية ، فاتصل بطبيبك (انظر القسم 3).</p><p dir="RTL">- صداع</p><p dir="RTL">- زيادة هرمون يسمى البرولاكتين في الدم</p><p dir="RTL">- رغبة مستمرة في التحرك (أكاثيسيا)</p><p dir="RTL">- صرير الأسنان (صرير الأسنان)</p><p dir="RTL">- عدم القدرة على فتح فمك (الكزاز / الطعن)</p><p dir="RTL">- متلازمة تململ الساق (تحث على تحريك الساقين لوقف الأحاسيس المؤلمة أو الغريبة ، والتي تحدث غالبًا في الليل)</p><p dir="RTL">- إفرازات حليبية غير طبيعية من الثدي (ثر اللبن)</p><p dir="RTL">-لوحظ زيادة خطر الاصابة بكسور بالعظام في المرضى الذين يتناولون هذا النوع من الأدوية.</p><p dir="RTL">تم الإبلاغ عن زيادة خطر العجز الجنسي عند تناول جرعة 20 ملغ، وفي بعض المرضى لوحظ هذا التأثير الجانبي عند تناول جرعات أقل.</p><p dir="RTL"><strong>أعراض جانبية إضافية لدى </strong><strong>الأطفال و</strong><strong>المراهقين</strong></p><p dir="RTL">كانت الآثار الجانبية التي لوحظت مع عقار الـفورتيوكسيتين في الأطفال و المراهقين مماثلة لتلك التي لوحظت عند البالغين باستثناء الأحداث المتعلقة بألم البطن التي لوحظت في كثير من الأحيان أكثر من البالغين والأفكار الانتحارية التي لوحظت في كثير من الأحيان لدى المراهقين أكثر من البالغين.</p><p dir="RTL">&nbsp;</p><p dir="RTL"><strong>الإبلاغ عن الآثار الجانبية</strong></p><p dir="RTL">إذا ظهرت لديك أية آثار جانبية، فتحدَّث إلى طبيبك أو الصيدلي الخاص بك. ويشمل ذلك أية آثار جانبية مُحتمَلة، غير المُدرجة في هذه النَّشرة.</p><p dir="RTL">بإبلاغكِ عن الآثار الجانبية، يمكنك المساعدة في توفير معلومات إضافية حول أمان استخدام هذا الدَّواء</p>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            <label class="h2" for="StorageConditionsAr">5. طريقة تخزين المستحضر</label>
        </div>
        <div class="m-r-60">
            <p dir="RTL"><strong>1.&nbsp;&nbsp;&nbsp; </strong><strong>كيفية تخزين عقار برينتيليكس</strong></p><p dir="RTL">&nbsp;</p><p dir="RTL">يُحفظ هذا الدَّواء بعيدًا عن رؤية ومُتناوَل الأطفال.</p><p dir="RTL">لا تستعمل هذا الدَّواء بعد انتهاء تاريخ الصَّلاحية المدون على العبوة بعد كلمة &quot;EXP&quot;. يُشير تاريخ انتهاء الصَّلاحية إلى اليوم الأخير من ذلك الشهر.</p><p>&nbsp;</p><p dir="RTL">لا تقم بالتَّخزين في درجة حرارة تتعدى 30 درجة مئوية.</p><p dir="RTL">لا تتخلص من الأدوية عن طريق إلقائها في مياه الصَّرف أو مع المخلفات المنزلية. استشر الصيدلي الخاص بك عن كيفية التَّخلص من الأدوية التي لم تعد تستخدمها. ستُساعد هذه التَّدابير على حماية البيئة</p>
        </div>
    </div>
    <div class="col-xs-12">
        <label style="float: right">6. معلومات أخرى</label>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="IngredientsAr">أ‌. على ماذا يحتوي هذا المستحضر</label>
        </div>
        <div class="m-r-60">
            <p dir="RTL"><strong>ما هي محتويات عقار برينتيليكس؟</strong></p><p dir="RTL"><strong>10 </strong><strong>ملجم</strong><strong>:</strong></p><p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; المادة الفعالة هي فورتيوكسيتين. يحتوي كل قرص مغلَّف على 10 ملجم فورتيوكسيتين (على هيئة هيدروبروميد).المكونات الأخرى هي مانِّيتول (E421)، سيليلوز فائق التبلور، هيدروكسي بروبيل السليلوز، جليكولات نشا الصوديوم (النوع أ)، ستيرات الماغنسيوم، هيبروميلوز، ماكروجول 400، ثاني أكسيد التيتانيوم E171))، أكسيد الحديد الأصفر (E172).</p><p>&nbsp;</p><p dir="RTL"><strong>20 </strong><strong>ملجم</strong><strong>:</strong></p><p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; المادة الفعالة هي فورتيوكسيتين. يحتوي كل قرص مغلَّف على 20 ملجم فورتيوكسيتين (على هيئة هيدروبروميد).</p><p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; المكونات الأخرى هي مانِّيتول (E421)، سيليلوز فائق التبلور، هيدروكسي بروبيل السليلوز، جليكولات نشا الصوديوم (النوع أ)، ستيرات الماغنسيوم، هيبروميلوز، ماكروجول 400، ثاني أكسيد التيتانيوم (E171)، أكسيد الحديد الأحمر (E172).</p><p dir="RTL">&nbsp;</p>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="ShapeAndContentsAr">ب‌. كيف يبدو شكل هذا المستحضر وماهي محتويات العلبة</label>
        </div>
        <div class="m-r-60">
            <p dir="RTL"><strong>ما هو شكل عقار برينتيليكس؟ وما هي محتويات العبوة؟</strong></p><p dir="RTL"><strong>10 </strong><strong>ملجم</strong><strong>:</strong></p><p dir="RTL">أقراص مغلفة صفراء اللون، لوزية الشَّكل، مقاسها 5 &times; 8.4 مللي متر، على أحد جانبيها العلامة &quot;TL&quot; والرَّقم &quot;10&quot; على الجانب الآخر.</p><p dir="RTL"><strong>20 </strong><strong>ملجم</strong><strong>:</strong></p><p dir="RTL">أقراص مغلفة حمراء اللون، لوزية الشكل، مقاسها 5 &times; 8.4 مللي متر، على أحد جانبيها العلامة &quot;TL&quot; والرقم &quot;20&quot; على الجانب الآخر.</p><p dir="RTL">يتوفر عقار برينتيليكس أقراص مغلَّفة 10 ملجم و20 ملجم في علب تحتوي على 14 و28 قرصًا في شرائط. قد لا يتم تسويق جميع أحجام العبوات.</p>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="ManufacturingAndMarketingAr">ت‌. الشركة المصنعة ومالك حق التسويق</label>
        </div>
        <div class="m-r-60">
            <p dir="RTL">مالك حقوق التَّسويق</p><p dir="RTL"><strong>شركة أجا للصناعة الدَّوائية المحدودة</strong></p><p dir="RTL">حائل، المملكة العربية السعودية</p><p dir="RTL">&nbsp;</p><p dir="RTL"><strong>جهة التَّصنيع</strong></p><p dir="RTL">إتش لوندبيك شركة مساهمة</p><p dir="RTL">9 أوتيليافيج</p><p dir="RTL">2500 فالبي</p><p dir="RTL">الدنمارك</p>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="RevisionNoteAr">ث‌. تمت مراجعة هذه النشرة في التاريخ الذي تمت فيه مراجعة النشرة بالشهر والسنة</label>
        </div>
        <div class="m-r-60">
            تمت آخر مراجعة لهذه النَّشرة في  فبراير 2024
        </div>
    </div>
</div>
    </div>
    <div id="M-div" class="box-data">


    <div class="p-20 text-center font-22">
            <div class="p-10 bg-light-blue font-15 m-t-20 m-b-20 ltr"><i class="fa fa-info-circle"></i>&nbsp;Read this leaflet carefully before you start using this product as it contains important information for you</div>
    </div>
<div class="row clearfix ltr">

    <div class="col-xs-12">
        <div class="clearfix">
            <label style="float: left" for="MedicinalName">1. NAME OF THE MEDICINAL PRODUCT </label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                WARNING: SUICIDAL THOUGHTS AND BEHAVIORS Antidepressants increased the risk of suicidal thoughts and behavior in children, adolescents, and young adults in short-term studies. These studies did not show an increase in the risk of suicidal thoughts and behavior with antidepressant use in patients over age 24; there was a trend towards reduced risk with antidepressant use in patients aged 65 and older (see section 4.4).

In patients of all ages who are started on antidepressant therapy, monitor closely for worsening, and for emergence of suicidal thoughts and behaviors. Advise families and caregivers of the need for close observation and communication with the prescriber (see section
4.4).

Brintellix has not been evaluated for use in paediatric patients (see section 4.2).
NAME OF THE MEDICINAL PRODUCT

Brintellix 10 mg film-coated tablets
Brintellix 20 mg film-coated tablets

            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            <label style="float: left" for="QualitativeQuantitativeComposition">2. QUALITATIVE AND QUANTITATIVE COMPOSITION </label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                QUALITATIVE AND QUANTITATIVE COMPOSITION

Each film-coated tablet contains vortioxetine hydrobromide equivalent to 10/20 mg vortioxetine. For the full list of excipients, see section 6.1.

            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            <label style="float: left" for="DosageForm">3. PHARMACEUTICAL FORM </label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                PHARMACEUTICAL FORM

Film-coated tablet.

10 mg:
Yellow, almond-shaped (5 x 8.4 mm) film-coated tablet engraved with “TL” on one side and “10” on the other side.

20 mg:
Red, almond-shaped (5 x 8.4 mm) film-coated tablet engraved with “TL” on one side and “20” on the other side.

            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <label style="float: left">4. CLINICAL PARTICULARS</label>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="TherapeuticIndications">4.1 Therapeutic Indications</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p><strong>CL</strong><strong>INICAL PARTICULARS</strong></p><p>&nbsp;</p><p><strong>4.1&nbsp;&nbsp;&nbsp;&nbsp; Therapeutic indications</strong></p><p>&nbsp;</p><p>Brintellix is indicated for the treatment of major depressive disorders in adults.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="PosologyAndMethodAdministration">4.2 Posology And Method Administration</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p><strong>P</strong><strong>osology and method of administration</strong></p><p>&nbsp;</p><p><u>Posology</u></p><p>&nbsp;</p><p>The starting and recommended dose of Brintellix is 10 mg vortioxetine once daily without regards to meals.</p><p>&nbsp;</p><p>Depending on individual patient response, the dose may be increased to a maximum of 20 mg vortioxetine once daily or decreased to a minimum of 5 mg vortioxetine once daily.</p><p>&nbsp;</p><p>After the depressive symptoms resolve, treatment for at least 6 months is recommended for consolidation of the antidepressive response.</p><p>&nbsp;</p><p><u>T</u><u>r</u><u>eatment discontinuation</u></p><p>&nbsp;</p><p>A gradual reduction in dosage may be considered to avoid the occurrence of discontinuation symptoms (see section 4.8). However, there is insufficient data to provide specific recommendations for a tapering schedule for patients treated with Brintellix</p><p>&nbsp;</p><p><u>Special Population</u></p><p>&nbsp;</p><p><em>Elderly patients</em></p><p>The lowest effective dose of 5&nbsp;mg vortioxetine once daily should always be used as the starting dose in patients &ge;&nbsp;65 years of age. Caution is advised when treating patients &ge;&nbsp;65 years of age with doses higher than 10&nbsp;mg vortioxetine once daily for which data are limited (see section 4.4)</p><p><em>&nbsp;</em></p><p><em>C</em><em>ytochrome P450 inhibitors</em></p><p>Reduce the dose of Brintellix by one-half when patients are receiving a CYP2D6 strong inhibitor (e.g. bupropion, fluoxetine, paroxetine or quinidine) concomitantly. The dose should be increased to the original level when the CYP2D6 inhibitor is discontinued (see section 4.5).</p><p>&nbsp;</p><p><em>C</em><em>ytochrome P450 inducers</em></p><p>Consider increasing the dose of Brintellix when strong CYP inducer (e.g. rifampicin, carbamazepine or phenytoin) is co-administered for greater than 14 days. The maximum recommended dose should not exceed three times the original dose. The dose of Brintellix should be reduced to the original level within 14 days, when the inducer is discontinued (see section 4.5).</p><p>&nbsp;</p><p><em>Pediatric population</em></p><p>Brintellix should not be used in pediatric patients (under 18 years of age)with major depressive disorder (MDD) because efficacy has not been demonstrated (see section 5.1). The safety of Brintellix in pediatric patients is described in section 4.4, 4.8 and 5.1.</p><p>&nbsp;</p><p>Renal or hepatic impairment</p><p>No dose adjustment is needed based on renal or hepatic function (see section 4.4 and 5.2).</p><p>&nbsp;</p><p><u>Method of administration</u></p><p>&nbsp;</p><p>Brintellix is for oral use.</p><p>The film-coated tablets can be taken with or without food.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="Contraindications">4.3 Contraindications</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                Contraindications

Hypersensitivity to the active substance or to any of the excipients listed in section 6.1.



The use of MAOIs intended to treat psychiatric disorders with Brintellix or whitin 21 days of stopping treatment with Brintellix is contraindicated because if an increased risk of serotonin syndrome (see section 4.5).

The use of Brintellix within 14 days of stopping an MAOI intended to treat psychiatric disorders is also contraindicated (see section 4.5)
Starting Brintellix in a patient who is being treated with MAOIs such as linezolid or intravenous
methylene blue is also contraindicated because of an increased risk of serotonin syndrome (see 
section 4.5)


            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="SpecialWarnings">4.4. Special warnings and precautions for use</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p><u>U</u><u>se in pediatric population</u></p><p>&nbsp;</p><p>Brintellix should not be used in children and adolescents aged 7 to 17 years with MDD because efficacy has not been demonstrated (see section 5.1). In general , the adverse reaction profile of vortioxetine in children and adolescents was similar to that seen for adults except for a higher incidence of abdominal pain-related events, and a higher incidence of sucidal ideation in adolescents specifically, compared to adults (see section 4.8 and 5.1). In clinical studies in children and adolescents treated with antidepressants, suicide-related behavior (suicide attempt and suicidal thoughts) and hostility (predominantly aggression, oppositional behavior, anger) were more frequently observed than in those treated with placebo.</p><p>&nbsp;</p><p><u>Suicide/suicidal thoughts or clinical worsening</u></p><p>&nbsp;</p><p>Depression is associated with an increased risk of suicidal thoughts, self harm and suicide</p><p>(suicide-related events). This risk persists until significant remission occurs. As improvement may not occur during the first few weeks or more of treatment, patients should be closely monitored until such improvement occurs. It is general clinical experience that the risk of suicide may increase in the early stages of recovery.</p><p>&nbsp;</p><p>Patients with a history of suicide-related events or those exhibiting a significant degree of suicidal ideation prior to commencement of treatment are known to be at greater risk of suicidal thoughts or suicide attempts, and should receive careful monitoring during treatment. A meta-analysis of placebo-controlled clinical studies of antidepressants in adult patients with psychiatric disorders</p><p>showed an increased risk of suicidal behavior with antidepressants compared to placebo, in patients less than 25 years old.</p><p>&nbsp;</p><p>Close supervision of patients and in particular those at high risk should accompany treatment especially in early treatment and following dose changes. Patients (and caregivers of patients) should be alerted to the need to monitor for any clinical worsening, suicidal behavior or thoughts and unusual changes in behavior and to seek medical advice immediately if these symptoms present.</p><p>&nbsp;</p><p><u>Seizures</u></p><p>&nbsp;</p><p>Seizures are a potential risk with antidepressants. Therefore, Brintellix should be introduced cautiously in patients who have a history of seizures or in patients with unstable epilepsy (see section 4.5). Treatment should be discontinued in any patient who develops seizures or for whom there is an increase in seizure frequency.</p><p><u>Serotonin Syndrome (SS) or </u><u>Neuroleptic Malignant Syndrome (NMS)</u></p><p>The development of a potentially life-threatening serotonin syndrome (SS) or Neuroleptic Malignant Syndrome (NMS) has been reported with serotonergic antidepressants including Brintellix, when used alone but more often when used concomitantly with other seotonergic drugs (including Opioids and triptans, tricyclic antidepressants, fentanyl, lithium, tramadol, tryptophan, buspirone and St. John&rsquo;s Wort), and with drugs that impair metabolism of serotonin (in particular, MAOIs, both those intended to treat psychiatric disorders and also other, such as linezolid and intravenous methylene blue). Patients should be monitored for the emergence of signs and symptoms of SS or NMS</p><p>&nbsp;</p><p>Serotonin Syndrome symptoms may include mental status changes (e.g., agitation, hallucinations, delirium and coma), autonomic instability (e.g., tachycardia, labile blood pressure, dizziness, diaphoresis, flushing and hyperthermia), neuromuscular symptoms (e.g., tremor, rigidity, myoclonus, hyperreflexia and incoordination), seizures, and/or gastrointestinal symptoms (e.g., nausea, vomiting and diarrhea). Patients should be monitored for the emergence of serotonin syndrome.</p><p>&nbsp;</p><p>The concomitant use of Brintellix with MAOIs intended to treat psychiatric disorders is contraindicated. Brintellix should also not be started in a patient who is being treated with MAOIs such as linezolid and intravenous methylene blue. All reports with methylene blue that provided information on the route of administration involved intravenous administration in the dose range of 1 mg/kg to 8 mg/kg. No reports involved the administration of methylene blue by other routes (such as oral tablets or local tissue injection) or at lower doses. There may be circumstances when it is necessary to initiate treatment with a MAOI such as linezolid and intravenous methylene blue in a patient taking Brintellix. Brintellix should be discontinued before initiating treatment with the MAOI (see section 4.3 and 4.5).</p><p>&nbsp;</p><p>If concomitant use of Brintellix with other serotonergic drugs, including triptans, tricyclic antidepressants, fentanyl, lithium, tramadol, buspirone ,tryptophan and St. John&rsquo;s Wort is clinically warranted, patients should be made aware of a potential increased risk for serotonin syndrome, particularly during treatment initiation and dose increase. Treatment with Brintellix and any concomitant serotonergic agents should be discontinued immediately if the above events occur and supportive symptomatic treatment should be initiated.</p><p>&nbsp;</p><p><u>A</u><u>ngle Closure Glaucoma</u></p><p>The pupillary dilation that occurs following use of many antidepressant drugs, including Brintellix, may trigger an angle closure attack in a patient with anatomically narrow angles who dose not have a patent iridectomy.</p><p>&nbsp;</p><p><u>Mania/hypomania</u></p><p>&nbsp;</p><p>Brintellix should be used with caution in patients with a history of mania/hypomania and should be discontinued in any patient entering a manic phase.</p><p>&nbsp;</p><p>Aggression/agitation</p><p>Patients treated with antidepressants, including vortioxetine, may also experience feelings of aggres-sion, anger, agitation and irritability. Patient&rsquo;s condition and disease status should be closely monitored. Patients (and caregivers of patients) should be alerted to seek medical advice, if aggres-sive/agitated behavior emerges or aggravates.</p><p>&nbsp;</p><p><u>H</u><u>emorrhage</u></p><p>&nbsp;</p><p>Bleeding abnormalities, such as ecchymoses, purpura and other hemorrhagic events, such as gastrointestinal or gynaecological bleeding, have been reported rarely with the use of antidepressants with serotonergic effect, including vortioxetine. SSRIs/SNRIs may increase the risk of postpartum hemorrhage, and this risk could potentially apply also to vortioxetine (see section 4.6). Caution is advised in patients taking anticoagulants and/or medicinal products known to affect platelet function [e.g., atypical antipsychotics and phenothiazines, most tricyclic antidepressants, non-steroidal anti-inflammatory drugs (NSAIDs), acetylsalicylic acid (ASA)] (see section 4.5) and in patients with known bleeding tendencies/disorders.</p><p>&nbsp;</p><p><u>H</u><u>y</u><u>ponatraemia</u></p><p>&nbsp;</p><p>Hyponatraemia, probably due to inappropriate antidiuretic hormone secretion (SIADH), has been reported rarely with the use of antidepressants with serotonergic effect (SSRIs, SNRIs). Caution should be exercised in patients at risk, such as the elderly, patients with cirrhosis of the liver or patients concomitantly treated with medications known to cause hyponatraemia.</p><p>Discontinuation of Brintellix should be considered in patients with symptomatic hyponatraemia and appropriate medical intervention should be instituted.</p><p>&nbsp;</p><p>Glaucoma</p><p>&nbsp;</p><p>Mydriasis has been reported in association with use of antidepressants, including vortioxetine. This mydriatic effect has the potential to narrow the eye angle resulting in increased intraocular pressure and angle-closure glaucoma. Caution is advised when prescribing vortioxetine to patients with increased intraocular pressure, or those at risk of acute narrow-angle glaucoma.</p><p>&nbsp;</p><p><u>Elderly</u></p><p><u>&nbsp;</u></p><p>Data on the use of Brintellix in elderly patients with major depressive episodes are limited. Therefore, caution should be exercised when treating patients &ge; 65 years of age with doses higher than 10&nbsp;mg vortioxetine once daily impairment. Caution should therefore be exercised (see section 5.2).</p><p>&nbsp;</p><p><u>R</u><u>enal or hepatic impairment</u></p><p><u>&nbsp;</u></p><p><u>Given that subjects with renal or hepatic impairment are vulnerable and given that the data on the use of Brintellix in these subpopulations are limited, caution should be exercised when treating these patients.</u></p><p>&nbsp;</p><p>Limited data are available for patients with severe renal impairment. Caution should therefore be exercised (see section 4.2 and 5.2).</p><p>&nbsp;</p><p>Brintellix contains Sodium</p><p>This medicinal product contains less than 1 mmol sodium (23 mg) per tablet, that is to say essentially &lsquo;sodium-free&rsquo;.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="InteractionsOtherMedicines">4.5. Interactions with other medicinal products</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p><strong>Interaction with other medicinal products and other forms of interaction</strong></p><p>&nbsp;</p><p>Vortioxetine is extensively metabolized in the liver primarily through oxidation and subsequent glucuronic acid conjugation. <em>In vitro</em>, the cytochrome P450 isozymes CYP2D6, CYP3A4/5, CYP2C19, CYP2C9, CYP2A6, CYP2C8 and CYP2B6 are involved in the metabolism of vortioxetine (see section 5.2).</p><p>&nbsp;</p><p><u>Potential for other medicinal products to affect vortioxetine</u></p><p>&nbsp;</p><p><em>I</em><em>rreversible non-selective MAOIs</em></p><p>Due to the risk of Serotonin Syndrome, vortioxetine is contraindicated in any combination with irreversible non-selective MAOIs. Vortioxetine must not be initiated for at least 14 days after discontinuation of treatment with an irreversible non-selective MAOI. Vortioxetine must be discontinued for at least 14 days before starting treatment with an irreversible non-selective MAOI (see section 4.3).</p><p>&nbsp;</p><p><em>Reversible, selective MAO-A inhibitor (moclobemide)</em></p><p>The combination of vortioxetine with a reversible and selective MAO-A inhibitor, such as moclobemide, is contraindicated (see section 4.3). If the combination proves necessary, the added medicinal product should be given with minimum dosage and under close clinical monitoring for Serotonin Syndrome (see section 4.4).</p><p>&nbsp;</p><p><em>Reversible, non-selective MAOI (linezolid)</em></p><p>The combination of vortioxetine with a weak reversible and non-selective MAOI, such as the</p><p>antibiotic linezolid, is contraindicated (see section 4.3). If the combination proves necessary, the added medicinal product should be given with minimum dosage and under close clinical monitoring for Serotonin Syndrome (see section 4.4).</p><p>&nbsp;</p><p><em>I</em><em>rreversible, selective MAO-B inhibitor (selegiline, rasagiline)</em></p><p>Although a lower risk of Serotonin Syndrome is expected with selective MAO-B inhibitors than with MAO-A inhibitors, the combination of vortioxetine with irreversible MAO-B inhibitors, such as selegiline or rasagiline should be exercised with caution. Close monitoring for Serotonin Syndrome is necessary if used concomitantly (see section 4.4).</p><p>&nbsp;</p><p><em>Serotonergic medicinal products</em></p><p>Co-administration of medicinal products with serotonergic effect e.g. opioids (including tramadol) and triptans (including sumatriptan <em>&nbsp;</em>may lead to Serotonin Syndrome (see section 4.4).</p><p>&nbsp;</p><p><em>St. John&rsquo;s wort</em></p><p>Concomitant use of antidepressants with serotonergic effect and herbal remedies containing St. John&acute;s wort (<em>Hypericum perforatum</em>) may result in a higher incidence of adverse reactions including Serotonin Syndrome (see section 4.4).</p><p>&nbsp;</p><p><em>M</em><em>edicinal products lowering the seizure threshold</em></p><p>Antidepressants with serotonergic effect can lower the seizure threshold. Caution is advised when concomitantly using other medicinal products capable of lowering the seizure threshold [(e.g. antidepressants (tricyclics, SSRIs, SNRIs), neuroleptics (phenothiazines, thioxanthenes and butyrophenones), mefloquin, bupropion, tramadol)] (see section 4.4).</p><p>&nbsp;</p><p><em>ECT (electroconvulsive therapy)</em></p><p>There is no clinical experience with concurrent administration of vortioxetine and ECT, therefore caution is advisable.</p><p>&nbsp;</p><p><em>C</em><em>ytochrome P450 inhibitors</em></p><p>The exposure to vortioxetine increased 2.3-fold for Area Under Curve (AUC) when vortioxetine</p><p>10 mg/day was co-administered with bupropion (a strong CYP2D6 inhibitor 150 mg twice daily) for</p><p>14 days in healthy subjects. Co-administration resulted in a higher incidence of adverse reactions when bupropion was added to vortioxetine than when vortioxetine was added to bupropion. Depending on individual patient response, a lower dose of vortioxetine may be considered if strong</p><p>CYP2D6 inhibitors (e.g. bupropion, quinidine, fluoxetine, paroxetine) are added to vortioxetine treatment (see section 4.2).</p><p>&nbsp;</p><p>When vortioxetine was co-administered following 6 days of ketoconazole 400 mg/day (a CYP3A4/5 and P-glycoprotein inhibitor) or following 6 days of fluconazole 200 mg/day (a CYP2C9, CYP2C19, and CYP3A4/5 inhibitor) in healthy subjects, a 1.3-fold and 1.5-fold increase, respectively in vortioxetine AUC was observed. No dose adjustment is needed.</p><p>&nbsp;</p><p>No inhibitory effect of 40 mg single-dose omeprazole (CYP2C19 inhibitor) was observed on the multiple-dose pharmacokinetics of vortioxetine in healthy subjects.</p><p>&nbsp;</p><p>Co-administration of strong inhibitors of CYP3A4 and CYP2C9 to CYP2D6 poor metabolisers has not been investigated specifically, but it is anticipated that it will lead to increased exposure of</p><p>vortioxetine in these patients (see section 5.2).</p><p>&nbsp;</p><p><em>C</em><em>ytochrome P450 inducers</em></p><p>When a single dose of 20 mg vortioxetine was co-administered following 10 days of rifampicin</p><p>600 mg/day (a broad inducer of CYP isozymes) in healthy subjects, a 72% decrease in AUC of vortioxetine was observed. Depending on individual patient response, a dose adjustment may be considered if a broad cytochrome P450 inducer (e.g. rifampicin, carbamazepine, phenytoin) is added to vortioxetine treatment (see section 4.2).</p><p>&nbsp;</p><p><em>Alcohol</em></p><p>May enhance the adverse/toxic effect of Selective Serotonin Reuptake Inhibitors. Specifically, the risk</p><p>of psychomotor impairment may be enhanced. Patients receiving selective serotonin reuptake inhibitors should be advised to avoid alcohol. Monitor for the increased psychomotor impairment in patients who consume alcohol during treatment</p><p>&nbsp;</p><p>No effect on the pharmacokinetics of vortioxetine or ethanol and no significant impairment, relative to placebo, in cognitive function was observed when vortioxetine single doses of 20 mg or 40 mg was co-administered with a of single dose of ethanol (0.6 g/kg) in healthy subjects.</p><p>&nbsp;</p><p><em>Acetylsalicylic acid</em></p><p>No effect of multiple doses of acetylsalicylic acid 150 mg/day on the multiple-dose pharmacokinetics of vortioxetine was observed in healthy subjects.</p><p>&nbsp;</p><p><u>Potential for vortioxetine to affect other medicinal products</u></p><p>&nbsp;</p><p><em>Anticoagulants and antiplatelet medicinal products</em></p><p>No significant effects, relative to placebo, were observed in INR, prothrombin or plasma</p><p>R-/S-warfarin values following co-administration of multiple doses of vortioxetine with stable doses of warfarin in healthy subjects. Also, no significant inhibitory effect, relative to placebo, on platelet aggregation or pharmacokinetics of acetylsalicylic acid or salicylic acid was observed when acetylsalicylic acid 150 mg/day was co-administered following multiple doses of vortioxetine administration in healthy subjects. However, as for other serotonergic medicinal products, caution should be exercised when vortioxetine is combined with oral anticoagulants or antiplatelet medicinal products or medicines used for pain relief (e.g. acetylsalicylic acid (ASA) or NSAIDs), due to a potential increased risk of bleeding attributable to a pharmacodynamic interaction (see section 4.4).</p><p>&nbsp;</p><p><u>Potential pharmacokinetic interactions</u></p><p>&nbsp;</p><p><em>C</em><em>ytochrome P450 substrates</em></p><p><em>I</em><em>n vitro, </em>vortioxetine did not show any relevant potential for inhibition or induction of cytochrome P450 isozymes (see section 5.2).</p><p>&nbsp;</p><p>Following multiple doses of vortioxetine, no inhibitory effect was observed in healthy subjects for the cytochrome P450 isozymes CYP2C19 (omeprazole, diazepam), CYP3A4/5 (ethinyl estradiol, midazolam), CYP2B6 (bupropion), CYP2C9 (tolbutamide, S-warfarin), CYP1A2 (caffeine) or CYP2D6 (dextromethorphan).</p><p>&nbsp;</p><p>No pharmacodynamic interactions were observed. No significant impairment, relative to placebo, in cognitive function was observed for vortioxetine following co-administration with single 10 mg dose of diazepam. No significant effects, relative to placebo, were observed in the levels of sex hormones following co-administration of vortioxetine with a combined oral contraceptive (ethinyl estradiol</p><p>30 &micro;g/ levonorgestrel 150 &micro;g).</p><p>&nbsp;</p><p><em>Lithium, tryptophan</em></p><p>No clinically relevant effect was observed during steady-state lithium exposure following co- administration with multiple doses of vortioxetine in healthy subjects. However, there have been reports of enhanced effects when antidepressants with serotonergic effect have been given together with lithium or tryptophan, therefore concomitant use of vortioxetine with these medicinal products should be undertaken with caution.</p><p>&nbsp;</p><p>Interference with urine drug screens</p><p>There have been reports of false positive results in urine enzyme immunoassays for methadone in patients who have taken vortioxetine. Caution should be exercised in the interpretation of positive urine drug screen results, and confirmation by an alternative analytical technique (e.g., chromatographic methods) should be considered.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="FertilityAndPregnantWarnings">4.6. Fertility, pregnancy and lactation</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p><strong>F</strong><strong>e</strong><strong>rtility, pregnancy and lactation</strong></p><p>&nbsp;</p><p><u>Pregnancy</u></p><p>&nbsp;</p><p>Pregnancy Category C</p><p>&nbsp;</p><p>There are limited data from the use of vortioxetine in pregnant women. Vortioxetine should not be</p><p>used during pregnancy unless the clinical condition of the woman requires treatment with vortioxetine.</p><p>&nbsp;</p><p>The following symptoms may occur in the newborn after maternal use of aserotonergic medicinal product in later stages of pregnancy: respiratory distress, cyanosis, apnoea, seizures, temperature instability, feeding difficulty, vomiting, hypoglycaemia, hypertonia, hypotonia, hyperreflexia, tremor, jitteriness, irritability, lethargy, constant crying, somnolence and difficulty sleeping. These symptoms could be due to either discontinuation effects or excess serotonergic activity. In the majority of instances, such complications began immediately or soon (&lt;24 hours) after delivery.</p><p>&nbsp;</p><p>Epidemiological data suggest that the use of SSRIs in pregnancy, particularly in late pregnancy, may increase the risk of persistent pulmonary hypertension in the newborn (PPHN). Although no studies have investigated the association of PPHN with vortioxetine treatment, this potential risk cannot be ruled out taking into account the related mechanism of action (increase in serotonin concentrations).</p><p>&nbsp;</p><p>Animal studies did not demonstrate a teratogenic effect of vortioxetine, but effects on foetal weight and delayed ossification were seen (see section 5.3).</p><p>&nbsp;</p><p>Observational data have provided evidence of an increased risk (less than 2-fold) of postpartum hemorrhage following exposure to an SSRI or SNRI within the month prior to birth. Although no studies have investigated an association between vortioxetine treatment and postpartum hemorrhage, there is a potential risk, taking into account the related mechanism of action (See section 4.4)</p><p>&nbsp;</p><p><u>B</u><u>r</u><u>east-feeding</u></p><p>&nbsp;</p><p>Available data in animals have shown excretion of vortioxetine/ vortioxetine metabolites in milk. It is expected that vortioxetine will be excreted into human milk (see section 5.3).</p><p>&nbsp;</p><p>A risk to the suckling child cannot be excluded.</p><p>&nbsp;</p><p>A decision must be made whether to discontinue breast-feeding or to discontinue/abstain from Brintellix treatment taking into account the benefit of breast-feeding for the child and the benefit of therapy for the woman.</p><p>&nbsp;</p><p><u>Fertility</u></p><p>Fertility studies in male and female rats showed no effect of vortioxetine on fertility, sperm quality or mating performance (see section 5.3).</p><p>Human case reports with medicinal products from the related pharmacological class of antidepressants (SSRIs) have shown an effect on sperm quality that is reversible. Impact on human fertility has not been observed so far.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="EffectsAbilityDriveMachines">4.7. Effects on ability to drive and use machines</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p><strong>E</strong><strong>ff</strong><strong>ects on ability to drive and use machines</strong></p><p>&nbsp;</p><p>No significant impairment, relative to placebo, in driving performance, cognitive function or other psychomotor skills (using a battery of neuropsychological tests) was observed when healthy subjects were administered single and multiple doses of 10 mg/day vortioxetine. However, patients should exercise caution when driving or operating hazardous machinery.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="UndesirableEffects">4.8. Undesirable effects</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p><strong>U</strong><strong>ndesirable effects</strong></p><p><strong>&nbsp;</strong></p><p>Adverse reactions are listed below using the following convention: very common (&ge;1/10); common (&ge;1/100 to &lt;1/10); uncommon (&ge;1/1,000 to &lt;1/100); rare (&ge;1/10,000 to &lt;1/1,000); very rare (&lt;1/10,000), not known (cannot be estimated from the available data).&nbsp; The list is based on information from clinical trials and post-marketing experience.</p><p>&nbsp;</p><p>&nbsp;</p><p>&nbsp;</p><p>&nbsp;</p><p>&nbsp;</p><p>&nbsp;</p><p>&nbsp;</p><p>&nbsp;</p><p>&nbsp;</p><p>&nbsp;</p><p>&nbsp;</p><p>&nbsp;</p><p>&nbsp;</p><p>&nbsp;</p><p>&nbsp;</p><p>&nbsp;</p><table border="1" cellspacing="0" cellpadding="0" style="width:612px"><tbody><tr><td style="vertical-align:top"><p>SYSTEM ORGAN CLASS</p></td><td style="vertical-align:top"><p>FREQUENCY</p></td><td style="vertical-align:top"><p>ADVERSE REACTION</p></td></tr><tr><td style="vertical-align:top"><p>Immune system disorders</p></td><td style="vertical-align:top"><p>Not known*</p></td><td style="vertical-align:top"><p>Anaphylactic reaction</p></td></tr><tr><td style="vertical-align:top"><p>Endocrine disorders</p></td><td style="vertical-align:top"><p>Not known *</p></td><td style="vertical-align:top"><p>Hyperprolactinaemia, in some cases associated with galactorrhoea</p></td></tr><tr><td style="vertical-align:top"><p>Metabolism and nutrition disorders</p></td><td style="vertical-align:top"><p>Not known *</p></td><td style="vertical-align:top"><p>Hyponatraemia</p></td></tr><tr><td rowspan="3" style="vertical-align:top"><p>Psychiatric disorders</p></td><td style="vertical-align:top"><p>Common</p></td><td style="vertical-align:top"><p>Abnormal dreams</p></td></tr><tr><td style="vertical-align:top"><p>Not known *</p></td><td style="vertical-align:top"><p>Insomnia</p></td></tr><tr><td style="vertical-align:top"><p>Not known *</p></td><td style="vertical-align:top"><p>Agitation, aggression (see section 4.4)</p></td></tr><tr><td rowspan="3" style="vertical-align:top"><p>Nervous system disorders</p></td><td style="vertical-align:top"><p>Common</p></td><td style="vertical-align:top"><p>Dizziness</p></td></tr><tr><td style="vertical-align:top"><p>Uncommon</p></td><td style="vertical-align:top"><p>Tremor</p></td></tr><tr><td style="vertical-align:top"><p>Not known *</p></td><td style="vertical-align:top"><p>Serotonin Syndrome</p><p>Headache</p><p>Akathisia,</p><p>Bruxism,</p><p>Trismus,</p><p>Restless leg syndrome</p></td></tr><tr><td rowspan="2" style="vertical-align:top"><p>Eye disorders</p></td><td style="vertical-align:top"><p>Uncommon</p></td><td style="vertical-align:top"><p>Blurred vision</p></td></tr><tr><td style="vertical-align:top"><p>Rare</p></td><td style="vertical-align:top"><p>Mydriasis (which may lead to acute narrow angle glaucoma - see section 4.4)</p></td></tr><tr><td rowspan="2" style="vertical-align:top"><p>Vascular disorders</p></td><td style="vertical-align:top"><p>Uncommon</p></td><td style="vertical-align:top"><p>Flushing</p></td></tr><tr><td style="vertical-align:top"><p>Not known*</p></td><td style="vertical-align:top"><p>Haemorrhage (including contusion, ecchymosis, epistaxis, gastrointestinal or vaginal bleeding)</p></td></tr><tr><td rowspan="2" style="vertical-align:top"><p>Gastrointestinal disorders</p></td><td style="vertical-align:top"><p>Very common</p></td><td style="vertical-align:top"><p>Nausea</p></td></tr><tr><td style="vertical-align:top"><p>Common</p></td><td style="vertical-align:top"><p>Diarrhoea,</p><p>Constipation,</p><p>Vomiting</p><p>Dyspepsia</p></td></tr><tr><td rowspan="3" style="vertical-align:top"><p>Skin and subcutaneous tissue disorders</p></td><td style="vertical-align:top"><p>Common</p></td><td style="vertical-align:top"><p>Pruritus, including pruritus generalised</p><p>Hyperhidrosis</p></td></tr><tr><td style="vertical-align:top"><p>Uncommon</p></td><td style="vertical-align:top"><p>Night sweats</p></td></tr><tr><td style="vertical-align:top"><p>Not known*</p></td><td style="vertical-align:top"><p>Angioedema</p><p>Urticaria</p><p>Rash</p></td></tr><tr><td style="vertical-align:top"><p>General disorder and administration site conditions</p></td><td style="vertical-align:top"><p>Not known</p></td><td style="vertical-align:top"><p>Discontinuation syndrome</p></td></tr></tbody></table><p>* Based on post-marketing cases</p><p>Clinical studies experience</p><p>Because clinical trials are conducted under widely varying conditions, adverse reaction rates observed in the clinical trials of a drug cannot be directly compared to rates in the clinical studies of another drug and may not reflect the rates observed in clinical practice.</p><p>&nbsp;</p><p>Patient exposure</p><p>Brintellix was evaluated for safety in 4746 patients (18 years to 88 years of age) diagnosed with MDD</p><p>who participated in pre-marketing clinical studies; 2616 of those patients were exposed to Brintellix in</p><p>6 to 8 weeks, placebo-controlled studies at dose renging from 5 mg to 20 mg once daily and 204 patients were exposed to Brintellix in a 24 week to 64 week placebo-controlled maintenance study at doses of 5 mg to 10 mg once daily. Patients from the 6 to 8 week studies continued into 12 month open-label studies. Of the 2586 patients were exposed to at least one dose of Brintellix in open-label studies, 1727 were exposed to Brintellix for six months and 885 were exposed for at least one year. Adverse reactions reported as reason for discontinuation of treatment</p><p>&nbsp;</p><p>In pooled 6 to 8 week placebo-controlled studies the incidence of patients who received Brintellix 5</p><p>mg/day, 10 mg/day, 15 mg/day and 20 mg/day and discontinued treatment because of an adverse reaction was 5 %, 6 % , 8 % and 8 %, respectively, compared to 4 % of placebo-treated patients, Nausea was the most common adverse reaction reported as reason for discontinuation.</p><p>Common adverse reactions in placebo-controlled MDD studies</p><p>The most commonly observed adverse reaction in MDD patients treated with Brintellix in 6 to 8</p><p>weeks placebo-controlled studies (incidence &gt; 5 % and at least twice the rate of placebo) were nausea, constipation and vomiting.</p><p>Table 1 shows the incidence of common adverse reactions that occurred in &ge;2 % of MDD patients treated with any Brintellix dose and at least 2 % more frequently than in placebo-treated patients in the 6 to 8 week placebo-controlled studies.</p><p>&nbsp;</p><table border="1" cellspacing="0" cellpadding="0"><tbody><tr><td colspan="4" style="vertical-align:top"><p><strong>Table 1. Common Adverse Reactions Occurring in &ge;2% of Patients Treated with any BRINTELLIX Dose and at Least 2% Greater than the Incidence in Placebo-treated Patients</strong></p><p>&nbsp;</p></td></tr><tr><td rowspan="2" style="vertical-align:top"><p><strong>System Organ Class</strong></p><p><strong>Preferred Term</strong></p></td><td style="vertical-align:top"><p><strong>BRINTELLIX</strong></p><p><strong>10 mg/day</strong></p></td><td style="vertical-align:top"><p><strong>BRINTELLIX</strong></p><p><strong>20 mg/day</strong></p></td><td style="vertical-align:top"><p><strong>Placebo</strong></p><p><strong>&nbsp;</strong></p></td></tr><tr><td style="vertical-align:top"><p>N=699 %</p></td><td style="vertical-align:top"><p>N=455 %</p></td><td style="vertical-align:top"><p>N=1621 %</p></td></tr><tr><td colspan="4" style="vertical-align:top"><p><strong>Gastrointestinal disorders</strong></p></td></tr><tr><td style="vertical-align:top"><p>Nausea</p></td><td style="vertical-align:top"><p>26</p></td><td style="vertical-align:top"><p>32</p></td><td style="vertical-align:top"><p>9</p></td></tr><tr><td style="vertical-align:top"><p>Diarrhea</p></td><td style="vertical-align:top"><p>7</p></td><td style="vertical-align:top"><p>7</p></td><td style="vertical-align:top"><p>6</p></td></tr><tr><td style="vertical-align:top"><p>Dry mouth</p></td><td style="vertical-align:top"><p>7</p></td><td style="vertical-align:top"><p>8</p></td><td style="vertical-align:top"><p>6</p></td></tr><tr><td style="vertical-align:top"><p>Constipation</p></td><td style="vertical-align:top"><p>5</p></td><td style="vertical-align:top"><p>6</p></td><td style="vertical-align:top"><p>3</p></td></tr><tr><td style="vertical-align:top"><p>Vomiting</p></td><td style="vertical-align:top"><p>5</p></td><td style="vertical-align:top"><p>6</p></td><td style="vertical-align:top"><p>1</p></td></tr><tr><td style="vertical-align:top"><p>Flatulence</p></td><td style="vertical-align:top"><p>3</p></td><td style="vertical-align:top"><p>1</p></td><td style="vertical-align:top"><p>1</p></td></tr><tr><td colspan="4" style="vertical-align:top"><p><strong>Nervous system disorders</strong></p></td></tr><tr><td style="vertical-align:top"><p>Dizziness</p></td><td style="vertical-align:top"><p>6</p></td><td style="vertical-align:top"><p>9</p></td><td style="vertical-align:top"><p>6</p></td></tr><tr><td colspan="4" style="vertical-align:top"><p><strong>Psychiatric disorders</strong></p></td></tr><tr><td style="vertical-align:top"><p>Abnormal dreams</p></td><td style="vertical-align:top"><p>&lt;1</p></td><td style="vertical-align:top"><p>3</p></td><td style="vertical-align:top"><p>1</p></td></tr><tr><td colspan="4" style="vertical-align:top"><p><strong>Skin and subcutaneous tissue disorders</strong></p></td></tr><tr><td style="vertical-align:top"><p>Pruritur*</p></td><td style="vertical-align:top"><p>2</p></td><td style="vertical-align:top"><p>3</p></td><td style="vertical-align:top"><p>1</p></td></tr></tbody></table><p>&nbsp; * Includes pruritus generalised</p><p>&nbsp;</p><p><strong>N</strong><strong>ausea</strong></p><p>Nausea was the most common adverse reaction and its frequency was dose-related (Table 2). It was usually considered mild or moderate in intensity and the median duration was 2 weeks. Nausea was more common in females than males. Nausea</p><p>most commonly occurred&nbsp;&nbsp; in&nbsp; the&nbsp; first&nbsp; week of&nbsp; BRINTELLIX treatment&nbsp; with&nbsp; 15 to 20% of&nbsp; patients experiencing&nbsp; nausea after&nbsp; I&nbsp; to 2 days of treatment.</p><p>Approximately 10% of patients taking BRINTELLIX 10 mg/day to 20 mg/day had nausea at the end of the 6 to 8 week placebo- controlled study.</p><p>&nbsp;</p><p><u>D</u><u>escription of selected adverse reactions</u></p><p>&nbsp;</p><p><em>Elderly patients</em></p><p>For doses &ge;10 mg vortioxetine once daily, the withdrawal rate from the studies was higher in patients</p><p>aged &ge;65 years.</p><p>For doses of 20 mg vortioxetine once daily, the incidences of nausea and constipation were higher in patients aged &ge;65 years (42% and 15%, respectively) than in patients aged &lt;65 years (27% and 4%, respectively)(see section 4.4).</p><p>&nbsp;</p><p><em>Sexual dysfunction</em></p><p>Difficulties in sexual desire, sexual performance&nbsp; and sexual satisfaction&nbsp; often occur as manifestations&nbsp; of&nbsp; psychiatric&nbsp; disorders,&nbsp; but they&nbsp; may also be consequences of pharmacologic treatment.</p><p>&nbsp;</p><p>In the MDD 6 to 8 week controlled&nbsp; trials of BRINTELLIX,&nbsp; voluntarily reported adverse reactions&nbsp; related&nbsp; to sexual&nbsp; dysfunction&nbsp; were captured&nbsp; as&nbsp; individual event&nbsp; terms.&nbsp; These event terms have been aggregated and the overall incidence was as&nbsp; follows. In&nbsp; male patients&nbsp; the overall&nbsp; incidence&nbsp; was&nbsp; 3%,&nbsp; 4%,&nbsp; 4%,&nbsp; 5%&nbsp; in BRINTELLIX&nbsp; 5&nbsp; mg/day,&nbsp; l 0 mg/day, 15&nbsp; mg/day,&nbsp; 20&nbsp; mg/day,&nbsp; respectively, compared&nbsp; to&nbsp; 2%&nbsp; in&nbsp; placebo.&nbsp; In female patients, the overall incidence was &lt;I%,</p><p>1%, &lt;1%, 2%&nbsp; in BRINTELLIX&nbsp; 5 mg/day, 10 mg/day, 15 mg/day, 20 mg/day, respectively, compared to &lt;1% in placebo.</p><p>&nbsp;</p><p>Because voluntarily reported adverse sexual reactions are known to be underreported, in part because patients and physicians may be reluctant to discuss them, the Arizona Sexual Experiences Scale (ASEX), a validated measure designed to identify sexual side effects, was used prospectively&nbsp; in seven placebo- controlled trials. The ASEX scale includes five questions that pertain to the following aspects of sexual function: 1) sex drive, 2) ease of arousal, 3) ability to achieve erection (men) or lubrication (women),&nbsp; 4) ease of reaching orgasm, and 5) orgasm satisfaction.</p><p>&nbsp;</p><p><!--[if gte vml 1]><v:group id="Group_x0020_56"
 o:spid="_x0000_s1026" style='position:absolute;left:0;text-align:left;
 margin-left:210.1pt;margin-top:92pt;width:.1pt;height:2.4pt;z-index:-1513;
 mso-position-horizontal-relative:page' coordorigin="4202,1840" coordsize="2,48"
 o:gfxdata="UEsDBBQABgAIAAAAIQC75UiUBQEAAB4CAAATAAAAW0NvbnRlbnRfVHlwZXNdLnhtbKSRvU7DMBSF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">
 <v:shape id="Freeform_x0020_57" o:spid="_x0000_s1027" style='position:absolute;
  left:4202;top:1840;width:2;height:48;visibility:visible;mso-wrap-style:square;
  v-text-anchor:top' coordsize="2,48" o:gfxdata="UEsDBBQABgAIAAAAIQDb4fbL7gAAAIUBAAATAAAAW0NvbnRlbnRfVHlwZXNdLnhtbHyQz07DMAyH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=
" path="m,48l,e" filled="f" strokecolor="#313131" strokeweight=".96pt">
  <v:path arrowok="t" o:connecttype="custom" o:connectlocs="0,1888;0,1840"
   o:connectangles="0,0"/>
 </v:shape><w:wrap anchorx="page"/>
</v:group><![endif]--><img width="2" height="5" src="file:///C:/Users/101623/AppData/Local/Temp/msohtmlclip1/01/clip_image001.gif" />The presence or absence of sexual dysfunction among patients entering clinical studies was based on their ASEX scores. For patients without sexual dysfunction at baseline (approximately 1/3 of the population across all treatment groups in each study), Table2 shows the incidence of patients that developed treatment-emergent sexual dysfunction when treated with BRINTELLIX or placebo in any fixed dose group. Physicians should routinely inquire about possible sexual side effects.</p><p>&nbsp;</p><table border="1" cellspacing="0" cellpadding="0"><tbody><tr><td colspan="4" style="vertical-align:top"><p><strong>Table 2</strong><strong> AS</strong><strong>E</strong><strong>X Incidence of Treatment Emergent Sexual Dysfunction *</strong></p></td></tr><tr><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p><strong>BRINTELLIX</strong></p><p><strong>10 mg/day</strong></p><p>N=94:86&dagger;</p></td><td style="vertical-align:top"><p><strong>BRINTELLIX</strong></p><p><strong>20 mg/day</strong></p><p>N=67:59&dagger;</p></td><td style="vertical-align:top"><p><strong>Placebo</strong></p><p>N=135:162&dagger;</p><p><strong>&nbsp;</strong></p></td></tr><tr><td style="vertical-align:top"><p>Females</p></td><td style="vertical-align:top"><p>23 %</p></td><td style="vertical-align:top"><p>34 %</p></td><td style="vertical-align:top"><p>20 %</p></td></tr><tr><td style="vertical-align:top"><p>Males</p></td><td style="vertical-align:top"><p>20 %</p></td><td style="vertical-align:top"><p>29 %</p></td><td style="vertical-align:top"><p>14 %</p></td></tr></tbody></table><p>&nbsp;</p><p>* Incidence based on number of subjects with sexual dysfunction during the study I number of subjects without sexual dysfunction at baseline. Sexual dysfunction was defined as a subject scoring any of the following on the ASEX scale at two consecutive visits during the study: 1) total score &ge;19;2) any single item &ge;5;3) three or more items each with a score &ge;4</p><p>&dagger; Sample size for each dose group is the number of patients (females:&nbsp; males) without sexual dysfunction at baseline.</p><p>&nbsp;</p><p>In the post-marketing setting cases of sexual dysfunction have also been reported with doses of vortioxetine below 20 mg.</p><p>&nbsp;</p><p><em>C</em><em>l</em><em>ass effect</em></p><p>Epidemiological studies, mainly conducted in patients 50 years of age and older, show an increased risk of bone fractures in patients receiving a drug from related pharmacological classes of antidepressants (SSRIs or TCAs). The mechanism behind this risk is unknown, and it is not known if this risk is also relevant for vortioxetine.</p><p>&nbsp;</p><p><em>Pediatric population </em></p><p>A total of 304 children aged 7 to 11 years and 308 adolescents aged 12 to 17 years with major depressive disorder (MDD) were treated with vortioxetine in two double-blind, placebo-controlled studies, respectively. In general, the adverse reaction profile of vortioxetine in children and adolescents was similar to that observed in adults except for a higher incidence of abdominal pain-related events, and a higher incidence of suicidal ideation in adolescents specially, compared to adults (see section 5.1).</p><p>&nbsp;</p><p>Two long-term open-label extension studies were performed with vortioxetine doses of 5 to 20 mg/day, and with a treatment duration of 6 months (N=662) and 18 months (N=94), respectively. Overall, the safety and tolerability profile of vortioxetine in the paediatric population after long-term use was comparable to what has been observed after short-term use.</p><p>&nbsp;</p><p><em>Symptoms upon discontinuation of vortioxetine treatment</em></p><p>In the clinical studies, discontinuation symptoms were systematically evaluated following abrupt cessation of vortioxetine treatment. There was no clinically relevant difference to placebo in the incidence or nature of the discontinuation symptoms after treatment with vortioxetine (see section 5.1). Cases describing discontinuation symptoms have been reported in the post-marketing setting and have included symptoms such as dizziness, headache, sensory disturbances (including paraesthesia, electric shock sensations), sleep disturbances (including insomnia), nausea and/or vomiting, anxiety, irritability, agitation, fatigue and tremor. These symptoms may occur within the first week of vortioxetine discontinuation</p><p>&nbsp;</p><p><u>R</u><u>eporting of suspected adverse reactions</u></p><p>&nbsp;</p><p>Reporting suspected adverse reactions after authorization of the medicinal product is important. It allows continued monitoring of the benefit/risk balance of the medicinal product. Healthcare professionals are asked to report any suspected adverse reactions via the national reporting system</p><p>&nbsp;</p><p><strong>Saudi Arabia:</strong></p><table border="1" cellspacing="0" cellpadding="0"><tbody><tr><td style="vertical-align:top"><p>&nbsp;</p><p>&middot; &nbsp;The National Pharmacovigilance Centre (NPC):</p><p>- Fax: +966-11-205-7662</p><p>- SFDA Call Center: 19999</p><p>- E-mail: npc.drug@sfda.gov.sa/</p><p>- Website: https://ade.sfda.gov.sa/</p><p>&nbsp;</p></td></tr></tbody></table><p>&nbsp;</p><p><strong>Other GCC States:</strong></p><table border="1" cellspacing="0" cellpadding="0"><tbody><tr><td style="vertical-align:top"><p>&nbsp;</p><p>- Please contact the relevant competent authority.</p><p>&nbsp;</p></td></tr></tbody></table><p>&nbsp;</p><p><strong>Adverse Reactions Following Abrupt Discontinuation of BRINTELLIX Treatment</strong></p><p>Discontinuation symptoms have been prospectively evaluated in patients taking BRINTELLIX</p><p>10 mg/day, 15 mg/day, and 20 mg/day using the Discontinuation-Emergent Signs and</p><p>Symptoms (DESS) scale in clinical trials. Some patients experienced discontinuation</p><p>symptoms such as headache, muscle tension, mood swings, sudden outbursts of anger,</p><p>dizziness, and runny nose in the first week of abrupt discontinuation of BRINTELLIX 15 mg/day</p><p>and 20 mg/day.</p><p>&nbsp;</p><p><strong>Laboratory Tests</strong></p><p>BRINTELLIX has not been associated with any clinically important changes in laboratory test</p><p>parameters in serum chemistry (except sodium), hematology and urinalysis as measured in</p><p>the 6 to 8 week placebo-controlled studies. Hyponatremia has been reported with the</p><p>treatment of BRINTELLIX [see Special warnings and precautions for use 4.4]. In the six month, double-blind, placebo-controlled phase of a long-term study in patients who had responded to BRINTELLIX during the initial 12 week, open-label phase, there were no clinically important changes in labtest parameters between BRINTELLIX and placebo-treated patients.</p><p>&nbsp;</p><p><strong>Weight</strong></p><p>BRINTELLIX had no significant effect on body weight as measured by the mean change from baseline in the 6 to 8 week placebo-controlled studies. In the 6-month, double blind, placebo-controlled phase of a long-term study in patients who had responded to BRINTELLIX during the initial 12-week, open-label phase, there was no significant effect on body weight between BRINTELLIX and placebo- treated patients.</p><p>&nbsp;</p><p>&nbsp;</p><p><strong>Vital Signs</strong></p><p>BRINTELLIX has not been associated with any clinically significant effects on vital signs, including systolic and diastolic blood pressure and heart rate, as measured in placebo-controlled studies.</p><p>Other Adverse Reactions Observed in Clinical Studies The following listing does not include reactions:</p><p>1) already listed in previous tables or elsewhere in labeling, 2) for which a drug cause was remote,</p><p>3) which were so general as to be uninformative, 4) which were not considered to have significant clinical implications, or 5) which occurred at a rate equal to or less than placebo.</p><p>Ear and labyrinth disorders &mdash; vertigo</p><p>Gastrointestinal disorders &mdash; dyspepsia</p><p>Nervous system disorders &mdash; dysgeusia</p><p>Vascular disorders &mdash; flushing</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="Overdoes">4.9. Overdoes</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p><strong>O</strong><strong>verdose</strong></p><p>&nbsp;</p><p>Ingestion of vortioxetine in the dose range of 40 to 75 mg has caused an aggravation of the following adverse reactions: nausea, postural dizziness, diarrhea, abdominal discomfort, generalized pruritus, somnolence and flushing.</p><p>&nbsp;</p><p>Post-marketing experience mainly concerns vortioxetine overdoses of up to 80 mg. In the majority of cases, no symptoms or mild symptoms were reported. The most frequently reported symptoms were nausea and vomiting.</p><p>&nbsp;</p><p>There is limited experience with vortioxetine overdoses above 80 mg. Following dosages several fold higher than the therapeutic dose range, events of seizure and serotonin syndrome have been reported.</p><p>&nbsp;</p><p>Management of overdose should consist of treating clinical symptoms and relevant monitoring. Medical follow-up in a specialized environment is recommended.</p><p>&nbsp;</p>
            </div>
        </div>
    </div>

    <div class="col-xs-12">
        <label style="float: left">5. PHARMACOLOGICAL PROPERTIES</label>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="PharmacodynamicProperties">5.1. Pharmacodynamic Properties</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p><strong>PHARMACOLOGICAL PROPERTIES</strong></p><p>&nbsp;</p><p><strong>5.1&nbsp;&nbsp;&nbsp;&nbsp; Pharmacodynamic properties</strong></p><p>&nbsp;</p><p>Pharmacotherapeutic group: Psychoanaleptics; Other antidepressants, ATC-code: N06AX26</p><p>&nbsp;</p><p><u>Mechanism of action</u></p><p>&nbsp;</p><p>The mechanism of action of vortioxetine is thought to be related to its direct modulation of serotonergic receptor activity and inhibition of the serotonin (5-HT) transporter. Non-clinical data indicate that vortioxetine is a 5-HT3, 5-HT7, and 5-HT1D receptor antagonist, 5-HT1B receptor partial agonist, 5-HT1A receptor agonist and inhibitor of the 5-HT transporter, leading to modulation of neurotransmission in several systems, including the serotonin, norepinephrine, dopamine, histamine, acetylcholine, GABA and glutamate systems. This multimodal activity is considered responsible for the antidepressant and anxiolytic-like effects and the improvement of cognitive function, learning and memory observed with vortioxetine in animal studies. In addition, a nonclinical behavioural study in male animals indicates that vortioxetine does not induce sexual dysfunction. However, the precise contribution of the individual targets to the observed pharmacodynamic profile remains unclear and caution should be applied when extrapolating animal data directly to man.</p><p>&nbsp;</p><p>In humans, two positron emission tomography (PET) studies have been conducted using 5-HT transporter ligands (11C-MADAM or 11C-DASB) to quantify the 5-HT transporter occupancy in the brain across different dose levels. The mean 5-HT transporter occupancy in the specific regions of interest was approximately 50% at 5 mg/day, 65% at 10 mg/day and increased to above 80% at</p><p>20 mg/day. Vortioxetine has shown clinical antidepressant effects at 5-HT transporter occupancies as low as 50%.</p><p>&nbsp;</p><p><u>C</u><u>li</u><u>n</u><u>i</u><u>cal efficacy and safety</u></p><p>&nbsp;</p><p>The efficacy and safety of vortioxetine have been studied in a clinical program that included more than 6,700 patients, of whom more than 3,700 were treated with vortioxetine in short-term</p><p>(&le;12 weeks) studies in major depressive disorder (MDD). Twelve double-blind, placebo controlled,</p><p>6/8-week, fixed-dose studies have been conducted to investigate the short-term efficacy of vortioxetine in MDD both in adults and in the elderly. The efficacy of vortioxetine was demonstrated across 9 of the 12 studies, as measured by improvement in the Montgomery and &Aring;sberg Depression Rating Scale (MADRS) &nbsp;or Hamilton Depression Rating Scale 24-item (HAM-D24 ) total score, and supported by clinical relevance as demonstrated by the proportions of responders and remitters and the improvement in Clinical Global Impression &ndash; Global Improvement (CGI-I) score.</p><p>&nbsp;</p><p>The efficacy of vortioxetine increased with increasing dose. Furthermore, vortioxetine, in the dose range of 5-20 mg/day, demonstrated efficacy on the broad range of depressive symptoms (assessed by improvement in all MADRS single&ndash;item scores) and on the anxiety symptoms in depression (assessed using the HAM-A total score).</p><p>&nbsp;</p><p><em>M</em><em>aintenance</em></p><p>The maintenance of antidepressant efficacy was demonstrated in a relapse-prevention study. Patients</p><p>in remission after an initial 12-week open-label treatment period with vortioxetine were randomised to vortioxetine 5 or 10 mg/day or placebo and observed for relapse during a double-blind period of at least 24 weeks (24 to 64 weeks). Vortioxetine was superior (p=0.004) to placebo on the primary outcome measure, the time to relapse of MDD, with a hazard ratio of 2.0; that is, the risk of relapse was two times higher in the placebo group than in the vortioxetine group.</p><p>&nbsp;</p><p>&nbsp;</p><p><em>Elderly</em></p><p>In the double-blind, placebo-controlled, 8-week, fixed-dose study in elderly (aged &ge;65 years) depressed patients, vortioxetine 5 mg/day was superior to placebo as measured by improvement in the MADRS and HAM-D24 total scores.</p><p>&nbsp;</p><p>In the dose range of 5 to 20 mg/day vortioxetine, efficacy and tolerability in the elderly was in line with the results in the adult population.</p><p>&nbsp;</p><p><em>Patients with severe depression or high levels of anxiety symptoms</em></p><p>Antidepressant efficacy was also demonstrated in severely depressed patients (baseline MADRS total score &ge;30) and in depressed patients with a high level of anxiety symptoms (baseline HAM-A total score &ge;20) in short-term studies including the study in the elderly and in the long-term relapse- prevention study. Vortioxetine was effective in these patients.</p><p><em>Patients with inadequate response to SSRI/SNRI treatment</em></p><p>In a 12-week, double-blind, flexible-dose, comparative study in patients with moderate to severe depression who switched antidepressant treatment after an inadequate response to an SSRI/SNRI for the current episode vortioxetine 10-20 mg/day was statistically significantly better than agomelatine</p><p>25-50 mg/day as measured by improvement in the MADRS total score. The clinical relevance was</p><p>supported by the proportion of remitters and improvement in CGI-I and Sheehan Disability Scale</p><p>(SDS) scores.</p><p>&nbsp;</p><p><em>C</em><em>ognitive dysfunction in depression</em></p><p>In a short-term study in MDD in the elderly (&ge;65 years of age), vortioxetine (5 mg/day) demonstrated</p><p>positive effects relative to placebo on a neuropsychological test of executive function, processing speed, and attention, the Digit Symbol Substitution Test (DSST), and on a test of learning and memory, the Rey Auditory Verbal Learning Test (RAVLT), whereas the active reference duloxetine separated from placebo on the RAVLT only.</p><p>&nbsp;</p><p>Further, vortioxetine was superior to placebo in a range of neuropsychological tests involving the above-mentioned cognitive processes in a study in MDD in adults (<u>&lt;</u>65 years of age). Vortioxetine (10 and 20 mg/day) was superior to placebo on the primary outcome measure, a composite cognition score comprising the two neuropsychological tests, the DSST and the RAVLT. An improved performance was seen across all secondary measures of cognitive performance and on a patient-reported outcome</p><p>of cognitive function.</p><p>&nbsp;</p><p>In both studies, the effect of vortioxetine was mainly an independent effect on cognitive performance rather than an indirect effect through improvement of depressive symptoms.</p><p>&nbsp;</p><p><em>H</em><em>ealth-related quality of life and overall functioning</em></p><p>Vortioxetine was superior to placebo in health-related quality of life, as assessed using the SF-36</p><p>Mental Component Summary and the Quality of Life Enjoyment Satisfaction Questionnaire total and life satisfaction scores. This was supported by clinically relevant improvements in the overall health rating as measured using EQ-5D (EuroQol index) and in the overall functioning as assessed using the Sheehan Disability Scale (SDS) total score in the areas of work, social life, and family life versus placebo or an active comparator (agomelatine). Furthermore, the superior effects relative to placebo in health related quality of life were maintained in the long-term relapse prevention study.</p><p>&nbsp;</p><p><em>Tolerability and safety</em></p><p>The safety and tolerability of vortioxetine have been established in short- and long-term studies across the dose range of 5 to 20 mg/day. For information on undesirable effects, see section 4.8.</p><p>&nbsp;</p><p>Vortioxetine did not increase the incidence of insomnia or somnolence relative to placebo.</p><p>&nbsp;</p><p>In clinical short- and long-term placebo-controlled studies, potential discontinuation symptoms were systematically evaluated after abrupt treatment cessation of vortioxetine.</p><p>There was no clinically relevant difference to placebo in the incidence or nature of the discontinuation symptoms after either short-term (6-12 weeks) or long-term (24-64 weeks) treatment with vortioxetine.</p><p>&nbsp;</p><p>The incidence of self-reported adverse sexual reactions was low and similar to placebo in clinical short- and long-term studies with vortioxetine. In studies using the Arizona Sexual Experience Scale (ASEX), the incidence of treatment-emergent sexual dysfunction (TESD) and the ASEX total score showed no significant difference to placebo in symptoms of sexual dysfunction for doses 5-20 mg/day, however higher doses were associated with a numerical increase in TESD.</p><p>&nbsp;</p><p>The effect of vortioxetine on sexual function was further evaluated in an 8-week, double-blind, flexible-dose, comparative study (n=424) versus escitalopram in patients treated for at least 6 weeks with an SSRI (citalopram, paroxetine, or sertraline), with a low level of depressive symptoms (baseline CGI-S &le; 3) and TESD induced by the prior SSRI treatment. Vortioxetine 10-20 mg/day had statistically significantly less TESD than escitalopram 10-20 mg/day as measured by change in the CSFQ-14 total score (2.2 points, p=0.013) at week 8. The proportion of responders was not significantly different in the vortioxetine group (162 (74.7%)) compared with the escitalopram group (137 (66.2%)) at week 8 (OR 1.5 p=0.057). The antidepressant effect was maintained in both treatment groups.</p><p>&nbsp;</p><p>Vortioxetine had no effect relative to placebo on body weight, heart rate, or blood pressure in clinical short- and long-term studies.</p><p>&nbsp;</p><p>No clinically significant changes were observed in hepatic and renal assessments in clinical studies.</p><p>&nbsp;</p><p>Vortioxetine has not shown any clinically significant effect on ECG parameters, including the QT,</p><p>QTc, PR and QRS intervals, in patients with MDD. In a thorough QTc study in healthy subjects at</p><p>doses up to 40 mg daily, no potential for the prolongation of the QTc interval was observed.</p><p>&nbsp;</p><p><em>Paediatric population</em></p><p>Two short-term, randomised, double-blind, placebo-controlled, fixed-dose (vortioxetine 10 mg/day and 20 mg/day), active-referenced (fluoxetine), efficacy and safety studies have been conducted; one in children aged 7 to 11 years with MDD, and one in adolescents aged 12 to 17 years with MDD. The studies included a 4-week single-blind placebo lead-in period with standardized psychosocial intervention (treated patients in children study N=677, adolescent study N=777) and only non-responders from the lead-in period were randomised (children study N=540, adolescent study N=616).</p><p>&nbsp;</p><p>In the study in children aged 7 to 11 years, the average effect of the two vortioxetine doses 10 and 20 mg/day was not statistically significantly different from placebo based on the Children&acute;s Depression Rating Scale-Revised (CDRS-R) total score at week 8, nor was the active reference (fluoxetine 20 mg/day), nor did the individual vortioxetine doses (10 and 20mg/day) show a nominally significant difference from placebo. In general, the adverse event profile of vortioxetine in children was similar to that seen for adults, except for higher incidence of abdominal pain reported in children. Discontinuation due to adverse events was 2.0% in patients treated with vortioxetine 20 mg/day, 1.3% for vortioxetine 10 mg/day, 0.7% for placebo, and no discontinuations for fluoxetine. The most commonly reported adverse events in the vortioxetine treatment groups were nausea, headache, vomiting, dizziness, and abdominal pain. The incidence of nausea, vomiting and abdominal pain was higher in the vortioxetine groups than in the placebo group. Suicidal ideation and behaviour were reported as adverse events during the 4-week single-blind lead-in period (placebo 2/677 [0.3%]), and during the 8-week treatment period (vortioxetine 10 mg/day 1/149 [0.7%], placebo 1/153 [0.7%]). In addition, the event &lsquo;non-specific active suicidal thoughts&rsquo; was reported in the C-SSRS in 5 patients during the 8-week treatment period (vortioxetine 20 mg/day 1/153 [0.7%], placebo 1/153 [0.7%] and fluoxetine 3/82 [3.7%]). Suicidal ideation and behaviour as measured by Columbia-Suicide Severity Rating Scale (C-SSRS) was similar across treatment groups.</p><p>&nbsp;</p><p>In the study in adolescents aged 12 to 17 years neither vortioxetine 10 mg/day nor 20 mg/day was statistically significantly superior to placebo based on the Children&acute;s Depression Rating Scale-Revised (CDRS-R) total score. The active reference (fluoxetine 20 mg/day) separated statistically from placebo on the CDRS-R total score. In general, the adverse reaction profile of vortioxetine in adolescents was similar to that seen for adults except for higher incidences reported in adolescents than in adults for abdominal pain- and suicidal ideation. Discontinuation due to adverse events (mostly due to suicidal ideation, nausea and vomiting) was highest in patients treated with vortioxetine 20 mg/day (5.6%) as compared to vortioxetine 10 mg/day (2.7%), fluoxetine (3.3%), and placebo (1.3%). The most commonly reported adverse events in the vortioxetine treatment groups were nausea, vomiting and headache. Suicidal ideation and behavior were reported as adverse events both during the 4-week single-blind lead-in period (placebo 13/777 [1.7%]), and during the 8-week treatment period (vortioxetine 10 mg/day 2/147 [1.4%], vortioxetine 20 mg/day 6/161 [3.7%], fluoxetine 6/153 [3.9%], placebo 0/154 [0%]). Suicidal ideation and behavior as measured by C-SSRS was similar across treatment groups.</p><p>&nbsp;</p><p>Clinical studies on the use of vortioxetine in children and adolescents have not been conducted; therefore, the safety and efficacy of vortioxetine in the paediatric population have not been established (see section 4.2).</p><p>Brintellix should not be used in paediatric patients (under 18 years of age) with major depressive disorder (see section 4.2)</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
                <label style="float: left" for="PharmacokineticProperties">5.2. Pharmacokinetic Properties</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p><strong>P</strong><strong>harmacokinetic properties</strong></p><p>&nbsp;</p><p><u>A</u><u>bsorption</u></p><p>&nbsp;</p><p>Vortioxetine is slowly but well absorbed after oral administration and the peak plasma concentration is reached within 7 to 11 hours. Following multiple dosing of 5, 10, or 20 mg/day, mean Cmax values of 9 to 33 ng/mL were observed. The absolute bioavailability is 75%. No effect of food on the</p><p>pharmacokinetics was observed (see section 4.2).</p><p>&nbsp;</p><p>&nbsp;</p><p><u>D</u><u>i</u><u>stribution</u></p><p>&nbsp;</p><p>The mean volume of distribution (Vss&nbsp;) is 2,600 L, indicating extensive extravascular distribution. Vortioxetine is highly bound to plasma proteins (98 to 99%) and the binding appears to be independent of vortioxetine plasma concentrations.</p><p>&nbsp;</p><p><u>B</u><u>i</u><u>otransformation</u></p><p>&nbsp;</p><p>Vortioxetine is extensively metabolised in the liver, primarily through oxidation and subsequent glucuronic acid conjugation.</p><p>&nbsp;</p><p><em>I</em><em>n vitro</em>, the cytochrome P450 isozymes CYP2D6, CYP3A4/5, CYP2C19, CYP2C9, CYP2A6, CYP2C8, and CYP2B6 are involved in the metabolism of vortioxetine.</p><p>&nbsp;</p><p>No inhibitory or inducing effect of vortioxetine was observed <em>in vitro </em>for the CYP isozymes CYP1A2, CYP2A6, CYP2B6, CYP2C8, CYP2C9, CYP2C19, CYP2D6, CYP2E1, or CYP3A4/5. Vortioxetine is a poor P-gp substrate and inhibitor.</p><p>&nbsp;</p><p>&nbsp;</p><p>The major metabolite of vortioxetine is pharmacologically inactive.</p><p>&nbsp;</p><p><u>Elimination</u></p><p>&nbsp;</p><p>The mean elimination half-life and oral clearance are 66 hours and 33 L/h, respectively.</p><p>Approximately 2/3 of the inactive vortioxetine metabolites are excreted in the urine and approximately</p><p>1/3 in the faeces. Only negligible amounts of vortioxetine are excreted in the faeces. Steady-state plasma concentrations are achieved in approximately 2 weeks.</p><p>&nbsp;</p><p><u>Linearity/non-linearity</u></p><p>&nbsp;</p><p>The pharmacokinetics are linear and time independent in the dose range studied (2.5 to 60 mg/day).</p><p>&nbsp;</p><p>In accordance with the half-life, the accumulation index is 5 to 6 based on AUC0-24h following multiple doses of 5 to 20 mg/day.</p><p>&nbsp;</p><p><u>Special populations</u></p><p>&nbsp;</p><p><em>Elderly</em></p><p>In elderly healthy subjects (aged &ge;65 years; n=20), the exposure to vortioxetine increased up to 27%</p><p>(Cmax and AUC) compared to young healthy control subjects (aged &le;45 years) after multiple doses of 10 mg/day. No dose adjustment is needed (see section 4.2).</p><p>&nbsp;</p><p><em>Renal impairment</em></p><p>Following a single dose of 10 mg vortioxetine, renal impairment estimated using the Cockcroft-Gault formula (mild, moderate, or severe; n=8 per group) caused modest exposure increases (up to 30%), compared to healthy matched controls. In patients with end-stage renal disease, only a small fraction of vortioxetine was lost during dialysis (AUC and Cmax were 13% and 27% lower; n=8) following a single 10 mg dose of vortioxetine. No dose adjustment is needed based on renal function&nbsp; &nbsp;(see section 4.2 and 4.4).</p><p>&nbsp;</p><p><em>H</em><em>epatic impairment</em></p><p>&nbsp;</p><p>The pharmacokinetics in subjects (N = 6-8) with mild, moderate, or severe hepatic impairment (Child-Pugh Criteria A, B, or C, respectively) were compared to healthy volunteers. The changes in AUC were less than 10% lower in subjects with mild or moderate hepatic impairment, and 10% higher in those with severe hepatic impairment. The changes in Cmax were less than 25% lower in all groups. No dose adjustment is needed based on hepatic function (see section 4.2 and 4.4).</p><p>&nbsp;</p><p><em>C</em><em>Y</em><em>P2D6 poor metabolisers</em></p><p>The plasma concentration of vortioxetine was approximately two times higher in CYP2D6 poor metabolisers than in extensive metabolisers. <u>In the presence of strong CYP3A4/2C9-inhibitors, the</u> <u>exposure could potentially</u> be higher<u> (see section 4.5).</u> As for all patients, depending on individual patient response, a dose adjustment may be considered (see section 4.2).</p><p>&nbsp;</p><p><em>Pediatric population</em></p><p>Pharmacokinetics of vortioxetine in paediatric patients with major depressive disorder following oral administration of 5 to 20 mg once daily was characterized using population modeling analyses based on data from a pharmacokinetic study (7-17 years) and two efficacy and safety studies (7-17 years). The pharmacokinetics of vortioxetine in paediatric patients was similar to that observed in adult patients.</p><p><br />&nbsp;</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="PreclinicalSafetyData">5.3 Preclinical Safety Data</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p><strong>5.3&nbsp;&nbsp;&nbsp;&nbsp; Preclinical safety data</strong></p><p>&nbsp;</p><p>Administration of vortioxetine in the general toxicity studies in mice, rats and dogs was mainly associated with CNS-related clinical signs. These included salivation (rat and dog), pupil dilatation (dog), and one episode of convulsions in each of two dogs. A no-effect level for convulsions was established with a corresponding safety margin of 5 considering the maximum recommended therapeutic dose of 20 mg/day. Target organ toxicity was restricted to kidneys (rats) and liver (mice and rats). The changes in the kidney in rats (glomerulonephritis, renal tubular obstruction, crystalline material in renal tubule) and in the liver of mice and rats (hepatocellular hypertrophy, hepatocyte necrosis, bile duct hyperplasia, crystalline material in bile ducts) were seen at exposures more than 10- fold (mice) and 2-fold (rats) the human exposure at the maximum recommended therapeutic dose of</p><p>20 mg/day. These findings were mainly attributed to rodent-specific vortioxetine-related crystalline</p><p>material obstruction of the renal tubules and the bile ducts, respectively, and considered of low risk to humans.</p><p>&nbsp;</p><p>Vortioxetine was not genotoxic in a standard battery of <em>i</em><em>n vitro </em>and <em>in vivo </em>tests.</p><p>&nbsp;</p><p>Based on results from conventional 2-year carcinogenicity studies in mice or rats, vortioxetine is not considered to pose a risk of carcinogenicity in humans.</p><p>&nbsp;</p><p>Vortioxetine had no effect on rat fertility, mating performance, reproductive organs, or sperm morphology and motility. Vortioxetine was not teratogenic in rats or rabbits, but reproductive toxicity in terms of effects on foetal weight and delayed ossification were seen in the rat at exposures more than 10-fold the human exposure at the maximum recommended therapeutic dose of 20 mg/day. Similar effects were seen in the rabbit at sub-therapeutic exposure.</p><p>&nbsp;</p><p>In a pre- and post-natal study in rats, vortioxetine was associated with increased pup mortality, reduced bodyweight gain, and delayed pup development at doses that did not result in maternal toxicity and with associated exposures similar to those achieved in humans following administration of vortioxetine 20 mg/day (see section 4.6).</p><p>&nbsp;</p><p>Vortioxetine-related material was distributed to the milk of lactating rats (see section 4.6).</p><p>&nbsp;</p><p>In juvenile toxicity studies in rats, all vortioxetine treatment-related findings were consistent with those noted in adult animals.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <label style="float: left">6. PHARMACEUTICAL PARTICULARS</label>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="ExcipientsList">6.1 Excipients List</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p><strong>PHARMACEUTICAL PARTICULARS</strong></p><p><strong>&nbsp;</strong></p><p><strong>6.1&nbsp;&nbsp;&nbsp;&nbsp; List of excipients</strong></p><p>&nbsp;</p><p><u>T</u><u>ablet core</u></p><p>&nbsp;</p><p>Mannitol</p><p>Microcrystalline cellulose</p><p>Hydroxypropylcellulose</p><p>Sodium starch glycolate (type A) Magnesium stearate</p><p>&nbsp;</p><p><u>10 mg Tablet coating</u></p><p>&nbsp;</p><p>Hypromellose</p><p>Macrogol 400</p><p>Titanium dioxide (E171) Iron oxide yellow (E172)</p><p>&nbsp;</p><p><u>20 mg Tablet coating</u></p><p>&nbsp;</p><p>Hypromellose</p><p>Macrogol 400</p><p>Titanium dioxide (E171) Iron oxide red (E172)</p><p>&nbsp;</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="Incompatibilities">6.2. Incompatibilities</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Not applicable.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="ShelfLife">6.3. Shelf Life</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                48 months
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="PrecautionsStorageConditions">6.4. Special precautions for storage</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Do not store above 30 &deg;C.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="ContainerContents">6.5. Nature and contents of container</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Blister: Transparent; PVC/PVdC/aluminium blister. Pack size of 28 film-coated tablets.</p><p>&nbsp;</p><p>Not all strengths or pack sizes may be marketed.</p><p>&nbsp;</p><p>&nbsp;</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="SpecialPrecautionsDisposal">6.6. Special precautions for disposal and other handling</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Any unused medicinal product or waste material should be disposed of in accordance with local requirements.</p><p>&nbsp;</p><p>&nbsp;</p>
            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            <label style="float: left" for="AuthorizationMarketingHolder">7. MARKETING AUTHORISATION HOLDER</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                MARKETING AUTHORISATION HOLDER

AJA Pharmaceutical Industries Co
IndustrialCity, Hail,
Saudi Arabia
8.	MARKETING AUTHORISATION NUMBER(S)


Brintellix 10 mg: 0305233585 
Brintellix 20 mg: 1704233552 

            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            <label style="float: left" for="RevisionDateText">8. DATE OF REVISION OF THE TEXT</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                February 2024
            </div>
        </div>
    </div>
</div>

            }    </div>
    <div id="f-div" class="box-data">
        
<div class="row clearfix rtl">
    <div class="container-fluid">
        <!-- Basic Example -->
        <div class="col-lg-6 col-md-6 col-sm-6 col-xs-6">
            <div class="header">
                <h2>صورة المنتج على الرف</h2>
            </div>
            <div class="body">
                <div id="carousel-example-generic" class="carousel slide" data-ride="carousel">
                    <!-- Indicators -->
                    <ol class="carousel-indicators">
                        <li data-target="#carousel-example-generic" data-slide-to="0" class="active"></li>
                        <li data-target="#carousel-example-generic" data-slide-to="1" class=""></li>
                        <li data-target="#carousel-example-generic" data-slide-to="2" class=""></li>
                    </ol>
                    <!-- Wrapper for slides -->
                    <div class="carousel-inner" role="listbox">
                        <div class="item active">
                            
                                <img src="/images/nodrugimags.png">
                        </div>

                    </div>

                    <!-- Controls -->
                    <a class="left carousel-control" href="#carousel-example-generic" role="button" data-slide="prev">
                        <span class="glyphicon glyphicon-chevron-right" aria-hidden="true"></span>
                        <span class="sr-only">Previous</span>
                    </a>
                    <a class="right carousel-control" href="#carousel-example-generic" role="button" data-slide="next">
                        <span class="glyphicon glyphicon-chevron-left" aria-hidden="true"></span>
                        <span class="sr-only">Next</span>
                    </a>
                </div>
            </div>
        </div>
        <!-- #END# Basic Example -->
        <!-- With Captions -->
        <div class="col-lg-6 col-md-6 col-sm-6 col-xs-6">
            <div class="header">
                <h2>الصورة الاساسية</h2>
            </div>
            <div class="body">
                <div id="carousel-example-generic_2" class="carousel slide" data-ride="carousel">
                    <!-- Indicators -->
                    <ol class="carousel-indicators">
                        <li data-target="#carousel-example-generic_2" data-slide-to="0" class=""></li>
                        <li data-target="#carousel-example-generic_2" data-slide-to="1" class="active"></li>
                        <li data-target="#carousel-example-generic_2" data-slide-to="2"></li>
                    </ol>
                    <!-- Wrapper for slides -->
                    <div class="carousel-inner" role="listbox">
                        <div class="item active">
                                <img src="/images/nodrugimags.png">
                        </div>
                    </div>
                    <!-- Controls -->
                    <a class="left carousel-control" href="#carousel-example-generic_2" role="button" data-slide="prev">
                        <span class="glyphicon glyphicon-chevron-right" aria-hidden="true"></span>
                        <span class="sr-only">Previous</span>
                    </a>
                    <a class="right carousel-control" href="#carousel-example-generic_2" role="button" data-slide="next">
                        <span class="glyphicon glyphicon-chevron-left" aria-hidden="true"></span>
                        <span class="sr-only">Next</span>
                    </a>
                </div>
            </div>
        </div>
        <!-- #END# With Captions -->
    </div>
</div>


    </div>

    <!-- #END# Tabs With Custom Animations -->
</div>
        <a style="background-image: url('../images/banner.png');"
           class="scroll-top">
            <img style="margin: 15px;" src="/images/icons/up-arrow2.png" width="35">
        </a>

        <div class="footer navbar-fixed-bottom">
            <small style="color: white; margin-left: 30px;">All Rights Reserved - SFDA &copy; 2020</small>
            <br class="visible-xs visible-sm"><br class="visible-xs visible-sm">

        </div>
    </section>


    <script src="/lib/json2/json2.js?v=w3DjWhUtDqy3bSJKv285C-2kagUtW9F64T9z3xRah8g"></script>
    <script src="/lib/jquery/dist/jquery.js?v=w4hyv6-vmv08RC2hK00wXgxDziKII9paMAbU_M-5dgY"></script>
    <script src="/lib/bootstrap/dist/js/bootstrap.js?v=T574NvJTWc-Pan8hAmnXXc0eZFiqKRp7xQ3sz5QiFOk"></script>
    <script src="/lib/moment/min/moment-with-locales.js?v=5f0RFtuChrGi6osDzegxXWf5yOkmx45i7J9fM1p6P5w"></script>
    <script src="/lib/jquery-validation/dist/jquery.validate.js?v=ZDzsHzuLAtqQVxXwbgRtfAPXQ7UAoJRXBAUDvc9G9CI"></script>
    <script src="/lib/blockUI/jquery.blockUI.js?v=KKcUNqwNyTLaXzvuMyFk6JisiQq6Hk7ZtrciXnEf3Z0"></script>
    <script src="/lib/toastr/toastr.js?v=s1ewxfN8Vn23TAVRLUk8XiQUAw6uWhhuPO9dmtYzUiA"></script>
    <script src="/lib/sweetalert/dist/sweetalert.min.js?v=aPktydUv1rN3mouQeXoKi3ioFTIQlULuqYeoTAA2ihY"></script>
    <script src="/lib/spin.js/spin.js?v=b1plKpQIB-XuGyjWec42MhmhpPzEPzFI3OC8Ia0XIoc"></script>
    <script src="/lib/spin.js/jquery.spin.js?v=i7H7HL08ldqUANgfQInE7LlU2uWUdQMCJ-Q7-_zLutY"></script>
    <script src="/lib/bootstrap-select/dist/js/bootstrap-select.js?v=tXulJKckrq2j2wo8a9hvmXLDEQwhGviPTIYmEzy1dNI"></script>
    <script src="/lib/jquery-slimscroll/jquery.slimscroll.js?v=ESVSX4dkOxamaRoYfcqPM2FfErhgfxS60fp1Fa8ou1w"></script>
    <script src="/lib/Waves/dist/waves.js?v=ZOMv1vwqpT_ezNZGhvr9jJTr_jqu3lYHB7vmpxD7HmA"></script>
    <script src="/lib/push.js/push.js?v=w347yqiscLjM_TxUKpqeUA1LDR3w5vshQpxpTsgkLhE"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/abp.js?v=EjNSmvtPSqCVK_xG_aTvOp8hmVM_7vwyd3hg45CAMGk"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/libs/abp.jquery.js?v=XEXcdRYb4eN3XoQCbnM-BSR6UifHRLsXYDIVFZ7Oc6Q"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/libs/abp.toastr.js?v=h3viOCmHM1K7HnYUuJPDvLchk2Ge8CoKvl6ZJfICgII"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/libs/abp.blockUI.js?v=vMuHbqHh635SKL2RG2qsGGCDyHg1yFeGqhPKpS34g4k"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/libs/abp.spin.js?v=djoKib6ssm5DDzbXLe5pD7ayfFg3siaoEk-BFYzQlvI"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/libs/abp.sweet-alert.js?v=fPp3O_ILaqD0UHiR721w1i4iBtxo3NH7yfldI5dg0_I"></script>
    <script src="/js/admin.js?v=nakObLuf3yPs2VlWrIris5w-48c36X3YIRrxIis7IKQ"></script>
    <script src="/js/main.js?v=x_HDlXByl0okIi4i04d4Q_fNr85GPQi1W8gjs82s-n8"></script>
    <script src="/view-resources/Views/Shared/_Layout.js?v=36YkLzPJaGejZMB10f2T6f1rMVIzDKq96kjfcnxcLVg"></script>


        <script src="/lib/jquery-validation/src/localization/messages_ar.js?v=6kzy-p-PtvkHPWdHWyjMOIfwhBFlUYYv9jnF7zJnpUI"></script>

    <!-- Dynamic scripts of ABP system (They are created on runtime and can not be bundled) -->
    <script src="/AbpServiceProxies/GetAll?v=638865394571695575" type="text/javascript"></script>
    <script src="/AbpScripts/GetScripts?v=638865394571695575" type="text/javascript"></script>
    <script src="/lib/signalr-client/signalr.min.js?v=1yGr-J4NjYMQVt6LP6vocjHIWhO-BFQLfdCs8x1Mv-U"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/libs/abp.signalr-client.js?v=jTdZBAadu6DXq0iDTFX6vsn4q6bFhKm3XfN8Jz6dSmg"></script>
    
    <!-- View specific scripts -->
    
    <script src="/view-resources/Views/Home/Index.js?v=mAIakROmG_IlahImCtfrMSdaLPTG5Uoh6Z0hM1g3cxw"></script>
    <script src="/view-resources/Views/Home/Result.js?v=0pEgOuTQc8ZyJaaOpJCG7ytkKSCkzEMYCHEJfKDWu4k"></script>
    <script src="/view-resources/Views/Home/DrugsSearch.js?v=04aRniTG_ClH5tABzf7EDwQgWVpkDNpjeJUDSGvOK_Y"></script>

</body>
</html>